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ABSTRACT 
Oral administration of autoantigen is a promising method to induce oral tolerance in 
autoimmune diseases, such as multiple sclerosis. Multiple sclerosis (MS) is a complex 
disorder of the central nervous system. MS is caused by destruction of several brain 
antigens in myelin. In order to increase the efficiency of oral tolerance induction, 
lactobacilli were developed as a tool to deliver heterologous protein into the 
gastrointestinal tract. Lactobacillus spp. are a potential delivery vehicle for oral antigens 
because of their generally regarded as safe (GRAS) status, ability to persist in the acidic 
environment of human gastrointestinal tract and also their health benefit to the host.  The 
goal of this study was to utilize lactobacilli as a genetic tool for heterologous protein 
expression and display. Three strains of lactobacilli were selected, and they are L. 
acidophilus ATCC 4356, L. gasseri ATCC 33323, and L. salivarius ATCC 11741.  Two 
strategies have been discussed in this thesis to develop lactobacilli delivery system. The 
first strategy developed genetically modified lactobacilli which express myelin epitopes 
from proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG). Two 
series of vectors has been constructed which direct the expression of these antigens either 
anchored to the cell wall or secreted into the environment. However, we only confirmed 
that PLP epitopes expressed from cell lysate of recombinant L. acidophilus, which contained 
plasmid with only secreted signal. We decided to develop the second strategy.  The second 
strategy explored the non-covalent attachment of myelin epitopes to the cell wall of 
Lactobacillus spp. via cell wall binding domains. In this study, three non-covalent CWBD 
were selected including L. gasseri ATCC 33323 LysM domain-containing protein, L. gasseri 
iii 
 
ATCC 33323 Lysozyme M1, Bacterial SH3 domain and C-terminal membrane anchor 
domain of Lactococcus lactis subsp. cremoris MG1363 AcmA protein. Through working with 
these domains, we found that L. gasseri ATCC 33323 Lysozyme M1 – bacterial SH3 domain 
can successfully bind on the exterior cell surface to L. acidophilus ATCC 4356, L. gasseri 
ATCC 33323, and L. salivarius ATCC 11741. Therefore, SH3 domain may be a good tool for 
oral administration by binding heterologous epitopes to lactobacilli. In future study, myelin 
epitopes and SH3 domain fusion proteins need to be displayed on the cell wall surface of 
lactobacilli. An animal model of multiple sclerosis is also important to evaluate an immune 
response of lactobacilli delivery system.  
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 INTRODUCTION CHAPTER 1
1.1 Motivation 
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, 
which causes multiple locations in the brain, spinal cord and other areas of the body 
(Awad, 1984). Work by our collaborator Dr. Mangalam has identified several important 
epitopes implicated in MS. These epitopes serve as the autoantigen including proteolipid 
protein (PLP) amino acids: 37-71, 89-154, 179-238, 264-277 and myelin-oligodendrocyte 
glycoprotein (MOG) amino acids: 30-150 and 181-203.  
The diverse species of lactic acid bacteria (LAB) have been considered as a safe and 
convenient vehicle to delivery autoantigens or peptides in the human gastrointestinal tract 
(Pouwels, Leer, & Boersma, 1996). Initially, several mumbers of our lactobacilli culture 
collection were screened to identify isolates that were amenable to our genetic tools. From 
that group, we identified three strains that were good candidates for further study: L. 
acidophilus ATCC 4356, L. gasseri ATCC 33323, and L. salivarius ATCC 11741. These three 
strains were sent to Mayo Clinic where our collaborator (Ashu Mangalam) tested their 
inherent ability to suppress MS in a rodent model. Surprisingly, L. gasseri ATCC 33323 had 
a moderate suppressing effect; L. salivarius ATCC 11741 had a strong suppressing effect 
whereas L. acidophilus ATCC 4356 had no effect. Our collaborator was very excited about 
the inherent ability of L. salivarius ATCC 11741 to suppress the development of MS and we 
have decided to focus our future efforts on these three strains.  
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1.2 Objective 
The objective of this study is to deliver heterologous target peptides (PLP and MOG) by 
lactobacilli to promote tolerance in multiple sclerosis. The lactobacilli genetic tools that 
enable secreted and cell-wall anchored expression or cell wall binding on the surface of cell 
wall were developed.  
1.3 Organization of thesis  
Chapter 2 is a literature review. First, background of MS disease was introduced and 
the mucosal immunological responses of both pathogenic infection and food protein (oral 
tolerance) were described. Moreover, characteristics of lactobacilli as probiotics and their 
applications in food were discussed. Finally, lactobacilli as intestinal delivery system that 
applied for oral vaccination and oral tolerance was summarized.  
Chapter 3 is about constructing recombinant lactobacilli to express these epitopes 
(PLP, MOG or fusions of these two epitopes) under a promoter fused to a secretion signal 
with or without an anchoring signal. The method for plasmid construction and protein 
validation were described in this chapter. Some potential issues and problems for plasmid 
transformation and protein expression of lactobacilli in this experiment were also 
explained and discussed.  
Chapter 4 described the second strategy of heterologous protein display on the cell 
wall surface of lactobacilli by cell wall binding domain (CWBD). Three different CWBD 
were selected to fuse with either green fluorescence protein (GFP) or our target myelin 
epitopes. There were two aims of this experiment. The first aim is to test the binding 
affinity of these CWBD by observing a number of GFP_CWBD fusion proteins. The second 
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aim is to bind myelin epitopes_CWBD fusion protein to the surface of lactobacilli. The 
methods of construct plasmid and protein validation on the surface of lactobacilli were 
discussed.  
Finally, conclusions are listed in Chapter 5. Lactobacilli could be used as potential live 
carrier of heterologous protein. Different heterologous protein cell wall display strategies, 
expression system or CWBD system, may also be applicable for other LAB. Future studies 
were listed in this chapter as well.   
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 LITERATURE REVIEW CHAPTER 2
2.1 Multiple sclerosis 
Definition of MS 
Multiple sclerosis (MS) is a complex disorder of the central nervous system (CNS) 
(Franklin, Franklin, ffrench Constant, Edgar, & Smith, 2012). It is caused by the destruction 
of several neural antigens in myelin, including myelin basic protein (MBP), proteolipid 
protein (PLP), and myelin oligodendrocyte glycoprotein (MOG). Its name is from the 
sclerotic lesion or plaques, which occur in the white matter of the central nervous system. 
People with MS disease develop variable symptoms, including fatigue, pain, weakness, 
dizziness, walking difficulties, vision problem, bladder problems and bowel problems 
(Kenneth Murphy, 2012). An estimated 0.1% of the population, approximately 400,000 
people in United States and about 2.5 million people around the world have MS diseases, 
which are commonly diagnosed between the ages of 20 to 40. In United State, about 200 
new cases are diagnosed each week (Multiple sclerosis in America 2013.2013).                                                                                                                                                                   
Mechanism and risk factors 
Figure 2.1 shows the pathogenesis of multiple sclerosis. Lymphocytes and other blood 
cells usually do not cross the blood-brain barrier. However, unknown triggers cause these 
cells to cross this barrier from blood vessels. Leukocytes, macrophages and blood proteins 
start to enter the brain. Then, activated CD4 T cells autoreactive for neural antigens 
migrate out of the blood vessel, and they reencounter their specific autoantigen presented 
by MHC class II molecules on microglical cells. Microglia are macrophage-like cells of the 
innate immune system resident in the central nervous system, which can act as antigen-
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presenting cells. Inflammation causes increased vascular permeability and more TH17 and 
TH1 cells move into the brain. Cytokines and chemokines (IL-17 and IFN-g) are produced 
by the infiltrating effector T cells, and then recruit myeloid cells that enhance the 
inflammation. It recruits of T cells, B cells and innate immune cells to the site of the lesion. 
Autoreactive activities cause demyelination of myelin in the brain. (Kenneth Murphy, 
2012). 
The demyelination of myelin can be triggered by various factors. Although the cause of 
multiple sclerosis is still understudied, it is assumed that the cooperation of immunology, 
infections, genetics and environment factors are involved in MS. Current studies showed 
that smoking (Salzer et al., 2013), vitamin D deficiency (Martinelli et al., 2014), HLA 
haplotype (Callander, 2007), and Epstein-Barr virus (Salzer, Stenlund, & Sundstrom, 2014) 
could also heighten MS. Moreover, women are more likely develop this disease than men. 
The ratio of women with MS to men with MS is 2:1. Also, it will significantly raise the 
chance of developing the disease if their parent or sibling has MS. Additionally, MS is more 
prevalent in certain areas including the northern United States, southern Canada, Europe, 
New Zealand and southeastern Australia. 
Myelin protein 
The myelin sheath is a considerably extended and modified plasma membrane that 
surrounds nerve axons and support electrical impulses to transmit quickly and efficiently 
along the nerve cell (George J. Siegel, Bernard W. Agranoff, 1999). Protein components of 
the myelin sheath have been regarded as the targets of MS. (Ben Nun et al., 1996) reviewed 
possible target antigens based on their location, percent in CNS myelin, demyelinating 
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antibodies and T-cell reactivity in MS and identified the major myelin proteins involved in 
MS as PLP, MBP and MOG.  
There are several reasons why PLP become a great interest in studying as a potential 
target antigen in MS. First, PLP is the primary protein component of myelin in CNS (>50% 
of total protein) and plays a significant role in myelin structure and function (Roland 
Martin, 2010). PLP has been confirmed to be encephalitogenic (the antigen produce 
experimental allergic brain disease) in various animal models. (Takashi Yamamura, 1986) 
demonstrated PLP-induced experimental autoimmune encephalomyelitis (EAE, animal 
model of MS) with significant demyelination in rat. This study had a tremendous 
contribution for the study of autoimmune demyelination. PLP is also encephalitogenic 
produce demyelination in CNS in rabbits (Selmaj, 1991), guinea pigs (Yoshimura, 1985) 
and mice (J. L. Trotter, 1987). Furthermore, more demyelination was observed with PLP-
induced EAE compared to other myelin protein induced EAE, which infers that PLP-
induced EAE is more related model to MS (Tabira, 1988). In human study, 
immunodominant epitopes of PLP that can be processed from whole PLP by human antigen 
presenting cells (APC). These epitopes typically lie within the 30-60 and 180-230 regions of 
PLP (Greer, 1997; J. Trotter et al., 1998). 
MBP is the second most abundant protein, after PLP, in CNS. It is the most 
characterized human autoantigen so far, and comprising 30% of the total protein and about 
10% of dry weight of myelin (Moscarello, 1997). The T-cell response to MBP has been 
analyzed by several studies. One of them tested a kinetic response of peripheral blood 
mononuclear cells from MS patients and healthy individuals. A significant response to eight 
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MBP regions (1-24, 30-45, 78-99, 90-114, 105-129, 120-144, 135-159 and 150-170) have 
been identified in a majority MS patients (Mazza et al., 2002). Moreover, the immune 
response of MS is also associated with the major histocompatibility complex class II 
phenotype DR2. Compared to the healthy group, higher frequency of MBP specific T-cell 
lines react with a DR2-associated region of MBP was observed in MS patients (Ota, 1990; K. 
J. Smith, Pyrdol, Gauthier, Wiley, & Wucherpfennig, 1998).  
MOG is another important autoantigen associated to the pathogenesis of both MS and 
EAE. It is a minor component of the myelin sheath, comprising only about 0.05% of total 
myelin protein. Comparing peripheral blood lymphocytes in MS patients with control 
group, T-cell reactivity against MOG has been demonstrated (De Rosbo, 1993). In various 
animal studies, severe neurological disease was caused by immunization with MOG. The 
disease was similar with the clinical, pathological and immunological features of MS 
(Bernard et al., 1997; Linington, 1993). There are also a number of identified 
encephalitogenic epitopes of MOG, such as MOG 1-22, MOG 35-55 and MOG 92-106 in 
different animal models. Particularly, MOG 35-55 peptide is highly encephalitogenic and 
can induce strong T and B cell response (Amor, 1994; Ichikawa, 1996; Linington, 1993). 
Treatments and drugs 
In the past 30 years, a lot of effective treatments and drugs have been developed and 
are commercially available to slow progress of the disease or treat symptoms. Currently, 
there are a total number of eleven U.S. Food and Drug Administration (FDA)-approved 
therapies for MS, including Aubagio (teriflunomide), Avonex/ Rebif (IFNβ-1a), 
Betaseron/Betaferon/Extavia (IFNβ-1b), Copaxon (glatiramer acetate), Novantrone 
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(mitoxantrone), Tysabri (natalizumab), Gilenya (fingolimod), Plegridy (peginterferon-β1a) 
and Tecfidera (dimethyl fumarate) (National multiple sclerosis society.2014; Castro 
Borrero et al., 2012a).  All of these medications could help MS patients regulate their 
disease and enhance their comfort and quality of life. Each of these therapies has their dose 
or route, mechanism of action, clinic benefit and side effects. Depending on the individual 
MS patient and stages of illness, different drugs are selected. For example, patients with 
clinically isolated syndrome have a lower risk of conversion to clinically definite MS if they 
receive early treatment of IFN β-1b compared to delayed treatment (Kappos et al., 2009). 
Therefore, IFN-β should be considered as the first treatment in newly diagnosed MS 
patients. For patients who fail to respond to the first-line agents, alternative treatments 
may be used, such as natalizumab or fingolimod (summarized by Castro Borrero et al., 
2012a). 
Much research is investigating this disease and developing new treatments and drugs. 
In particular, therapies with acceptable is long-term safety and efficacy profiles of oral, 
intramuscular and subcutaneous agents need to be developed. Moreover, the ideal dosing, 
length of treatment and side effects are also key factors to decrease inflammation and 
relapse. 
2.2 Mucosal immunology 
The importance of the mucosal system 
The large internal body surface (about 400 m2) is bounded by mucosal epithelia, such 
as the gastrointestinal tract, the upper and lower respiratory tract and the urogenital tract. 
The mucosal surface is a crucial physic-chemical barrier to protect tissues from pathogenic 
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microorganisms. It could also present pathogens to the immune system (Cerf Bensussan & 
Gaboriau Routhiau, 2010) through their physiological activities, such as gas exchange, food 
absorption, sensory activities of eyes, nose, mouth and throat, and reproduction. On the 
other hand, because of their fragility and permeability, they can be infected easily by 
numerous bacteria and viruses. Mucosal infections include acute respiratory infections, 
diarrheal diseases, human immunodeficiency virus (HIV), tuberculosis, measles, whooping 
cough, hepatitis B, roundworm and hookworm. All of these diseases are significant health 
problems in the world and cause a large number of deaths (Kenneth Murphy, 2012). For 
instance, seasonal flu, one of the respiratory infections is caused by seasonal influenza. 
According to estimated data of annual influenza-associated deaths by the Centers for 
Disease Control and Prevention (CDC), it showed that the flu-associated death ranged from 
3,000 to about 49,000 people from year 1976-1977 seasons to the year 2006-2007 flu 
season (CDC, 2013).  
Intestinal mucosal response to infection  
The gut is the most frequent site of infection by pathogenic microorganisms, including 
many viruses and enteric bacteria, protozoans and multicellular helminths parasites, which 
can cause diseases in different ways. CDC has estimated that 31known pathogens and an 
unknown number of unspecified agents transmitted through food cause of 47.8 million 
foodborne illnesses, 127,839 hospitalizations and 3,037 deaths annually in US(CDC, 2011). 
Within those pathogens, Salmonella, Toxoplasma gondii, Listeria monocytogenes, Norovirus 
and Campylobacter spp. are the top five known pathogens contributing to foodborne 
illnesses resulting in death. Therefore, it is crucial to understand how they stimulate 
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immune responses. Essentially, pathogenic antigens are transported into the mucosa 
through microfold cells (M cell), which are specialized epithelial cells in a layer that 
separate the lymphoid tissues from the gut lumen. M cells can take up antigens from the gut 
lumen by endocytosis and phagocytosis. Then the M cell translocate to the subepithelial 
dome, which is rich in dendritic cells, T cells and B cells. After the transportation, antigens 
can be recognized by dendritic cell, and then T cells are activated sent out to the site of 
infection (Kenneth Murphy, 2012).  
Even though various enteric pathogens have similar routes into lymphoid tissue, the 
host has quite distinct immune responses tailored for every individual pathogen. For 
example, Salmonella, an important cause of foodborne illness, can enter the gut epithelial 
layer by three ways, including enter through M cell and infect microphage, directly invade 
gut epithelial cells, and luminal capture by dendritic cells. Then, chemokines and cytokines, 
which are small protein that produced by macrophages, recruit neutrophils and activate 
them. Also, dendritic cells loaded with antigens travel to the mesenteric lymph node and 
trigger an adaptive immune response (Cossart, 2004). In contrast, Shigella flexneri, which 
cause bacterial dysentery, is not directly recognized by macrophages and epithelial cell 
after pass through M cell. Once Shigellae penetrate gut epithelium, it starts to invade and 
spread to epithelial cells. Then, shigella antigen is recognized by nucleotide-binding 
oligomerization domain (NOD) and active the NFkB pathway, which induce the expression 
of pro-inflammatory genes and recruit neutrophils (Carneiro et al., 2009). 
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Commensal bacteria and food protein in the gut 
Clonal selection of lymphocytes is one of the most important principles for 
immunological tolerance. During lymphocyte differentiation, a large number of B- and T-
cell receptors can recognize numerous self-antigens. Consequently, most of the self-
reactive lymphocytes are removed by the process of central tolerance in thymus and bone 
marrow (Burnet, 1959). Although food protein and the microbiota contain many nonself-
antigens, they can be recognized by the adaptive immune system. The immune system is 
extremely talented to distinguish pathogens and innocuous antigens since it is 
inappropriate and wasteful to target inoffensive antigens for preserving immune response. 
Most of these antigens together with commensal bacteria exist in the natural mucosal 
immune system is not only innocent but also highly advantageous to the host. This is best 
observed in the GIT, which is exposed over 100 g of foreign protein per day in our diet and 
up to 1,012 commensal microorganisms per gram in the colon. These microorganisms are 
from thousands of species of bacteria and live in symbiosis with their host (Kenneth 
Murphy, 2012).   
At the moment that food protein antigen or commensal bacteria were first introduced 
into the GIT, like many other foreign antigens, their self-reactive T-cell was not deleted in 
the thymus during lymphocyte development. However, they usually do not induce 
inflammatory immune responses. The phenomenon that oral administration antigen 
induces the hyporesponsiveness in an immunogenic form is called oral tolerance (reviewed 
by D. W. Smith, 2005). Oral tolerance can be induced in various mechanisms in peripheral 
tolerance, including clonal deletion or anergy of T cells and active regulation by the 
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regulatory T cells (Treg). Innocuous antigens will be presented by major histocompatibility 
complex (MHC) class I and class II molecules on dendritic cells once they enter the gut 
epithelial layer. Nevertheless, peripheral tissues do not express co-stimulatory molecules, 
which is a significant molecule to induce inflammatory responses. Food antigen-reactive T-
cell becomes angergic or eliminated to prevent clonal expansion and immune response 
(Schwartz, 2003). Another mechanism is active suppression by Treg. CD103, a specific kind 
of dendritic cells, is most likely in charge of taking up food antigens after feeding to 
animals. Then the complex of CD 103 moves these antigens to the mesenteric lymph nodes, 
which lies between the layers of mesentery. This delivery action could enhance the 
production of gut-homing FoxP3-positive Treg cells, thereby, the systemic immune 
response was suppressed (Hand & Belkaid, 2010). Additionally, there are also many other 
important cytokines contribute to oral tolerance, such as TGF-β, IL-10 and IFN-g (Dubin & 
Kolls, 2008). 
2.3 Lactobacilli  
Lactobacillus spp. are generally defined as a group of Gram-positive, cocci or rods, non-
mobile, facultatively anaerobic, fermentative, non-spore forming and catalase-negative 
bacteria (Makarova et al., 2006). Many lactobacilli are highly associated with food 
fermentation where lactic acid production is needed and they are capable surviving in an 
acidic environment, blow pH of 4-5 (reviewed by Anjum et al., 2014). Lactobacillus spp. are 
not only widely found in fermented foods but also in the oral cavity and gastrointestinal 
tracts (E. Vaughan, de Vries, Zoetendal, Ben Amor, Akkermans, & de Vos, 2002a). 
Lactobacilli is also one of the most popular effective probiotic organisms, which are defined 
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as “living micro-organisms which, when administered in adequate amounts, confer a health 
benefits on the host” (WHO, 2001). It is important to understand their characteristics and 
probiotics properties in human and animals.   
Lactobacillus spp. classification  
Lactobacillus spp. is one of the main genres of LAB. Its other genera are Lactococcus, 
Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Weissella, Carnobacterium and 
Tetragenococcus (Klein, Pack, Bonaparte, & Reuter, 1998). Similar with other LAB genre, 
Lactobacillus spp. could go through two types of fermentation, either homofermentative or 
heterofermentative in order to metabolize hexose sugar. Lactic acid is the primary end 
product during the homofermentative pathway; lactic acid, CO2, acetic acid and ethanol are 
produced in the heterofermentative pathway (Kandler, 1983). The Lactobacillus has been 
classified into three subgenera depends on carbohydrate metabolism and different 
temperature growth: Streptobacterium, Betabacterium, and Thermobacterium (Sharpe, 
1981).  
Streptobacterium are facultative heterofermentative species which can ferment 
glucose, and grow at 15oC, not 45oC, such as L. plantarum, L. casei, and L. sakei. 
Betabacterium are strict heterofermentative species, e.g. L. brevis, L. fermentum and L. 
reuteri, and they form CO2 by glucose fermentation, and mostly hydrolyze arginine 
(Schillinger, 1987). Thermobacterium are strict thermophilic and homofermentative 
species including L. delbrueckii, L. acidophilus several other species. Thermobacterium, 
which differ from other two subgenera, grow at 45oC, but 15oC, do not ferment ribose, and 
do not the hydrolyze arginine (BARRE, 1978; Sharpe, 1979). 
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Protein transport pathways 
Some proteins, which are synthesized in the lactobacilli cytosol, will not be functional 
until they could embed or cross through the cytoplasmic membrane. There are principally 
seven routes for protein transport in Gram-positive bacteria. They are the secretion (Sec), 
twin-arginine translocation (Tat), flagella export apparatus (FEA), fimbrilin-protein 
exporter (FPE), holing (pore-forming), peptide-efflux ABC and the WXG100 secretion 
system (Wss) pathways (Desvaux, Hébraud, Talon, & Henderson, 2009). Current studies 
have evaluated protein secretion pathways of 13 published genomes of Lactobacillus spp. 
Based on these Lactobacillus genomes, they carry genes encoding Sec, FPE, peptide-efflux 
ABC and holin systems (reviewed by Kleerebezem et al., 2010).  
The Sec translocase is the most important secretion mechanism that transfers protein 
across the cytoplasmic membrane. It consists of a protein-conducting channel (the SecYEG 
complex), peripherally energy (ATP-driven motor protein, SecA), an accessory protein 
SecDF (yajC) and YidC membrane protein.  Secretory protein can be targeted to Sec 
translocase, specific to SecA, by their signal sequence or the assist of the molecular 
chaperone SecB. All Sec translocase targeted proteins contain an N-terminal signal peptide. 
The signal peptide contains three regions including the N region (positive charged), the H 
region (hydrophobic residues) and the C region (contain a signal peptidase cleavage site) 
(Driessen, Driessen, & Nouwen, 2008). During protein translocation, the signal peptide of 
precursor protein can be cleaved by signal peptidases (SPases). Different types of SPases 
have been found to recognize various cleavage site, such as AxAA cleavage site and lipobox 
cleavage site (Sutcliffe, 2002; van Roosmalen et al., 2004).  
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Other secretion mechanisms, FPE, peptide-efflux ABC and holin systems, contribute to 
different classes of protein or DNA translocation significantly. For example, holins are 
important integral membrane proteins that are associated with muralytic enzymes 
secretion pathway, which is a part of the cell lysis system (Wang, Smith, & Young, 2000). 
The FPE pathway is a mechanism allowing exogenous DNA transfer into naturally 
competent bacteria (I. Chen & Dubnau, 2004). The principal export pathway of 
antimicrobial peptides, including lantibiotics, bacteriocins and competence peptides, is 
peptide efflux ABC transporters (ATP-binding cassette transporters, (Håvarstein, 
Havarstein, Diep, & Nes, 1995). So far, functional ABC transporters have been identified in 
L. acidophilus and L. plantarum (Diep, 1996; Dobson, Sanozky Dawes, & Klaenhammer, 
2007). 
Cell-wall-binding domain (CWBD) of Lactobacilli 
After proteins transported across the Lactobacillus cytoplasmic membrane, they are 
either secreted and released from the bacterial cell or surface-associated to the cell wall. 
For these surface-associated proteins, CWBD plays a role of bridge between proteins and 
cell wall. The CWBD could be classified into two categories based on different binding 
mechanisms: covalently anchored and non-covalent CWBD (reviewed by Kleerebezem et 
al., 2010).  
Covalently anchored proteins have either a N- or C-terminal anchor sequence. As 
mentioned above, the Sec translocation pathway targeted protein contains N, H and C 
regions of signal peptides in N-terminal. During the Sec translocation process, the 
particular sequence of C region could be targeted by SPase, and their signal peptide can be 
16 
 
removed before the protein released. However, most of the Sec-translocated proteins do 
not contain the cleavage sites in C region (Zhou, Boekhorst, Francke, & Siezen, 2008), and 
will remain N-terminally-anchored to the cell membrane. In fact, a large number of N-
terminally membrane-anchored proteins have been predicted in Lactobacillus genomes. 
The majority of these proteins are involved in of signal transductions, protein turnover, 
competence and cell-envelop metabolism (Kleerebezem et al., 2010). Additionally, 
Lactobacillus genomes also encode a minor amount of C-terminally anchored proteins, but 
their functions are largely unknown. 
Lipoprotein is another covalent CWBD in lactobacilli secreted proteins. These proteins 
have a signal peptide and undergo Sec pathway. Similar with N- or C-terminally anchored 
protein, lipoprotein signal peptides also contain N, H and C regions, and their C region 
contains the lipbox motif, which is important for lipoprotein biogenesis machinery after 
transport.  In the process of covalent bonding of lipoprotein, first, Cys-residue in lipbox is 
diacylglyceryl modified by the lipoprotein discylglyceryl transferase. Then, N-terminal of 
the Cys-residue is cleaved by SPase and anchoring protein by thioether linkage. Majority of 
lipoproteins that found in Lactobacillus spp. are components of ABC transporters and 
adhesion proteins (Hutchings, Palmer, Harrington, & Sutcliffe, 2009). 
LPxTG-anchored proteins are a well-known family of protein as well, which can 
covalently attach to the peptidoglycan of cell wall. N-terminal of these proteins contains a 
signal sequence in its C region. The signal sequence will be removed by SPase upon 
secretion by Sec pathway. C-terminal of these proteins contain LPxTG (Leu-Pro-any-Thr-
Gly) cell-wall-sorting motif (Boekhorst, de Been, M. W. H. J., Kleerebezem, & Siezen, 2005) 
17 
 
that can be recognized and cleaved by sortase enzyme. When sortase enzyme, 
transpeptidase, targets Thr-Gly region, transpeptidation occurs and then the protein 
covalently attaches the threonine carboxyl group to the peptidoglycan on the cell wall 
(Marraffini, DeDent, & Schneewind, 2006). A number of sortase and LPxTG-motif 
containing protein were predicted in different Lactobacillus genomes, such as L. delbruekii 
bulgaricus ATCC-BAA-365 and ATCC11842 and L. plantarum WFSI (Kleerebezem et al., 
2010). 
Non-covalent CWBD protein is another important subset of surface-associated protein. 
Within this subgroup, the LysM (Pfam PF01476) domain is commonly utilized. It consists of 
repeat units of a small LysM motif and usually able to be found in many extracellular 
enzymes. LysM domain has the capability to anchor proteins to the peptidoglycan layer of 
Gram-positive bacteria (Buist, Steen, Kok, & Kuipers, 2008). Currently, widespread 
utilization of the LysM domain has been used for detection of bacteria and display of 
enzymes and proteins on the extracellular surface of Lactobacillus spp. (Visweswaran et al., 
2014). 
The SLH domain, CWBD of S-layer protein, is typically a part of extracellular 
carbohydrate-binding proteins and contains 10-15 conserved amino acids (Jarosch, 2000). 
S-layer protein, which is paracrystalline monolayer, can non-covalently anchor to the 
peptidoglycan-associated polymers through an S-layer homology (SLH) domain (Fujino, 
1993; Lupas, 1994). Recently, more than 40 SLH containing proteins have been found in 
Gram-positive bacteria (Engelhardt & Peters, 1998). The large number of S-layer proteins 
has also been identified in L. acidophilus, L. helveticus and L. brevis (Åvall Jääskeläinen, 
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AVALLJAASKELAINEN, & PALVA, 2005; Goh et al., 2009; Vilen et al., 2009). Furthermore, 
the SLH domain has developed into a sufficient tool to display heterologous antigens to the 
cell wall (Mesnage, Tosi Couture, & Fouet, 1999). 
Another popular non-covalent CWBD is the eukaryotic SH3 domain. This domain can 
target and anchor proteins to the peptidoglycan layer by recognition of specific sequences 
within the cross-linking peptide bridges (Xu et al., 2011). Several proteins containing SH3 
have been identified in some Lactobacillus spp., such as L. brevis ATCC 367, L. casei ATCC 
334, L. gasseri ATCC 33323, L. plantarum WCFS1, and most of their functions are in cell wall 
turnover (Kleerebezem et al., 2010). 
Application of Lactobacilli in food and their probiotics characteristics 
The lactobacilli, generally recognized as safe (GRAS), are one of the predominant 
bacteria that widely utilized in food fermentation. They can be obtained from the yogurt, 
cheese, fermented milk, sausage and other fermented foods. Lactobacillus spp. are also 
indigenous to food habitats, like cereal grains, vegetables, fruits, and milk environments 
(Carr, Chill, & Maida, 2002). Their ancient anthropological role in food preservation is to 
ferment carbohydrate to lactic acid and provide the acidic environment for food material 
(Kleerebezem et al., 2003). Acidifying raw materials could enhance texture, flavor, 
microbial safety, increase shelf-life, control putrefactive microorganisms and resistant to 
microbial spoilage and food toxin (Rhee, Lee, & Lee, 2011). Lactobacilli also produce lots of 
other compounds to including natural antimicrobial substances, sugar polymers, 
sweeteners, enzymes and vitamins (Leroy & De Vuyst, 2004).  
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Lactobacilli are usually found in dairy and meat fermentations and even oral cavity 
(Ahrné et al., 1998; Colloca, 2000). Some Lactobacillus strains, like L. delbrueckii subsp 
bulgaricus, L. acidophilus, L. rhamnosus, L. reuteri and L. casei, have been used in probiotic 
preparations for human consumption (Fooks, Fuller, & Gibson, 1999). Lactobacilli belong to 
the original microflora of humans and colonize many locations of the body (Axelsson L, 
2004), thus different Lactobacillus spp. confer health benefits in various ways. In following 
three paragraphs, L. acidophilus, L. gasseri and L. salivarius are discussed in terms of food 
utilization and their probiotic effects. 
L. acidophilus is one of the most prevalent organisms for dietary use (N. Shah, 2007) 
and major commercial species of lactic acid bacteria. It is widely accessible in milk, yogurt, 
toddler formula and other supplements products (M. E. Sanders, 2001). It also involved in 
the production of fermented soymilk and different kind of cheese, such as cheddar cheese, 
minas fresh cheese, probiotic white cheese and Gouda cheese (reviewed by Anjum et al., 
2014). Historically, L. acidophilus has been utilized as part of starter cultures for milk 
fermentation and preservation for more than 10000 years (Tamime, 2002), and 80% of the 
yogurts contain L. acidophilus in the United State (M. Sanders, 2003). This species was not 
only added in the milk as a part of starter culture, but also be added for additional probiotic 
value (N. P. Shah, 2000). Probiotic strains of lactobacilli were discovered in many 
commercial food and pharmaceutical products (Yeung, 2002). (N. Shah, 2007) has 
summarized primary commercial probiotic strains of L. acidophilus, including L. acidophilus 
LA-1/LA-5 (Chr. Hansen), L. acidophilus NCFM (Rhodia), L. acidophilus La1(Nestle), L. 
acidophilus DDS-1 (Nebraska Culture), L. acidophilus SBT-2062 (Snow Brand Milk 
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products). L. acidophilus NCFM is the most common probiotic strain and well characterized.  
The characteristics of the probiotic strain have been showed in both physiology 
experiments and the context of feeding studies (Bull, Plummer, Marchesi, & 
Mahenthiralingam, 2013). In these physiological studies, the probiotic possess the 
capabilities to be stable in food products, resist to bile, survive in low pH, attach to human 
colonocytes in cell culture, produce antimicrobial and induce lactase activity. Additionally, 
probiotic effects also were observed in feeding studies. It has been found the effects of 
mediation of host immune system, lowering host serum cholesterol, improving host lactose 
metabolism and preventing or treating infections (reviewed by Bull et al., 2013). 
Furthermore, the probiotic effects of L. acidophilus have been investigated in several 
clinical trials. For example, probiotics containing L. acidophilus NCFM could reduce bloating 
in patients with bowel disorders (Ringel Kulka et al., 2011), suppress cold and influenza-
like symptoms in children (Leyer, Li, Mubasher, Reifer, & Ouwehand, 2009) and suppress 
diet-induced hypercholesterolemia (Dheeraj, Kansal, Nagpal, Yamashiro, & Marotta, 2013). 
L. gasseri plays an important role for food preservation because of its production of 
Gassericin A, which was first described in 1991. It is produced by L. gasseri LA 39, 
comprises 58 amino acids and carries a head-to-tail peptide bond to form circular 
bacteriocins (Kawai et al., 2001; Kawai, 1998). Bacteriocins have been identified as 
antimicrobial ribosomal peptides or proteinaceous complex that is made by both Gram-
positive and Gram-negative bacteria. The circular structure of Gassericin A makes it less 
susceptible to proteolytic cleavage and tolerant of high pH and temperature (Pandey, Malik, 
Kaushik, & Singroha, 2013). Gassericin A has also shown activities against several 
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foodborne pathogenic bacteria, such as Listeria monocytogenes, Bacillus cereus and 
Staphylococcus aureus (Kawai et al., 2001; Kawai, 1998). Interestingly, only limited strains 
of Lactobacillus produce this kind of bateriocins. Gassericin A from L. gasseri LA 39 is the 
first bacteriocin that showed the inhibition of food-borne pathogenic bacteria (Itoh, 1995). 
Moreover, L. gasseri also possesses probiotics properties on human health. L. gasseri can 
colonize in many areas in humans, including the GIT, oral cavity and vagina. That indicates 
its prevalence as commensal bacteria in healthy adults (Delgado, 2007; HOJO et al., 2007; 
Pot, B., LUDWIG, W., Kersters, K., SCHLEIFER, K., 1994).  Consumption of L. gasseri 
potentially contributes to maintaining of gut homeostasis. Several studies showed that 
consumption of L. gasseri in probiotics treatment could increase the concentration of 
butyrate (Olivares, Diaz Ropero, Martin, Rodriguez, & Xaus, 2006), increase IgA secretion in 
the mucosal layer to reduce fecal cytotoxicity and decrease Salmonella choleraesuis 
infection (Margreiter, 2006). 
L. salivarius is not a common species in starter cultures for food fermentation, but it is a 
promising probiotic species which heighten intestinal health (Neville & OToole, 2010). Five 
potential probiotics characteristics of L. salivarius have been summarized, and all of their 
properties indicate that L. salivarius could be an effective probiotic (Messaoudi et al., 2013). 
First, L. salivarius is resistant to acid and bile and able to adhere to intestinal cell. The high 
survival rate of L. salivarius CECT 5713 was obtained in an in vitro model of the human 
stomach and the small intestine, and the bacterium was firmly attaching to intestinal cells 
(Caco-2 and HT-29). The similar properties have been showed in L. salivarius SMXD51 as 
well (Maldonado et al., 2010; Messaoudi et al., 2012; Neville & OToole, 2010). Second, L. 
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salivarius should be safe to use both in vitro and vivo. For example, L. salivarius CECT 5713 
has been demonstrated to be reliable in animal model and its behavior is similar with 
another probiotics Lactobacillus strains (Martín et al., 2006; Olivares et al., 2006). 
Moreover, antimicrobial activity of probiotic L. salivarius has been investigated in several 
studies. A number of L. salivarius, which were isolated from chicken intestine, have activity 
to against Salmonella and Campylobacter jejuni (Zhang et al., 2011). Another study showed 
the production of bacteriocin Abp 118 from L. salivarius UCC118 showed capacities to 
protect mice from infection by Listeria monocytogenes (Corr et al., 2007). Furthermore, 
probiotic bacteria could stimulate the immune system and protect the host from intestinal 
diseases. L. salivarius  B1, L. salivarius CECT 5713 and L. salivarius UCC118, have been 
showed to improve host immunity by inducing different cytokines, such as Interleukin (IL)-
10, IL-6 and IL-12 (Riboulet Bisson et al., 2012; Sierra et al., 2010; Zhang et al., 2011). L. 
salivarius SMXD51 was also found to help host fighting against pathogenic infection by the 
production of antimicrobial β-defensin 2 (Schlee et al., 2008).  
2.4 Mucosal delivery of therapeutic molecules using LAB 
LAB and other delivery systems 
The primary entry for microorganism is mucosal surface (Sansonetti, 2004). 
Consequently, the immune system is very important at the mucosal surface (Kenneth 
Murphy, 2012). Mucosal immunization has been considered as an inexpensive and 
convenient technology to induce immunity in the mucosal surface. Several immunological 
studies showed that a delivery system is required to increase the uptake of antigen, avoid 
degradation in the gastrointestinal tract, and also stimulate adaptive immune responses 
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(Lavelle & OHagan, 2006; Neutra & Kozlowski, 2006). A number of live bacterial delivery 
systems have been developed for oral administration, including live attenuated pathogens 
and food-grade bacteria. Live attenuated pathogen, such as Salmonella typhi (Dertzbaugh, 
1998) and Mycobacterium (Stover, 1993), are made by eliminating their virulence while 
maintaining their immunostimulation (Dertzbaugh, 1998). Over the past decades, 
researchers have designed vaccine strains of attenuated Salmonella spp. That met the 
balance between immunogenicity and the reactogenicity and minimized side effects in vivo 
(Tacket & Levine, 2007). However, the reversion of attenuated pathogens to wild-type 
phenotype is still considered as a potential risk in humans. Therefore, commensal and 
food-grade bacteria are safer alternative delivery vehicles because of their GRAS status 
(Dieye et al., 2003a; Zegers et al., 1999a).  
Because of the unique properties of LAB that mentioned above in human 
gastrointestinal tract, it has been assessed as a candidate live oral delivery vector. One of 
the biggest advantages of LAB delivery system is their abilities to trigger the secretion of 
IgA response in addition to induce systemic immune response in many current vaccine 
(Lavelle & OHagan, 2006; Mannam, Jones, & Geller, 2004; Neutra & Kozlowski, 2006). 
Additionally, (Wells & Mercenier, 2008) reviewed several significant advantages of LAB as 
oral delivery vehicles, including survived through the human gastrointestinal tract, safety, 
stimulating both systemic and mucosal immune response by immigrating to Peyer’s 
patches and expressing target molecules and adjuvants. Additionally, they can also be 
engineered to express heterologous antigens and adjuvants. 
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Vaccine delivery 
In the last decade, numbers of researchers have developed recombinant LAB as genetic 
vaccine delivery tools for expression of heterologous protein (de Vos, 1999).  Various 
strains of carrier, different cellular location and amount of expressed antigen could 
influence immune response to the host.  
A single model antigen, tetanus toxin fragment C (TTFC) was investigated by 
expressing in three different bacterial strains, Lactococcus lactis, Lactobacillus spp. and 
Streptococcus gordonii in the murine gastrointestinal tract, oral cavity or vaginal cavity 
(Hanniffy et al., 2004a; Mercenier, 2000; Norton, 1996a). According to the results of several 
studies, the expressions of TTFC from Lactococcus lactis and Lactobacillus spp. have been 
shown to elicit protective immune response against tetanus toxin.  However, for some 
perspectives, the results cannot compare with each other directly because they are 
inconsistent in dosage and other parameters (Wells & Mercenier, 2008). This discovery 
could imply that it is important to select strains of LAB when designing mucosal vaccine, 
because their expressed protein may perform differently to the immune system.  
Moreover, the final cellular location of heterologous protein, including cytoplasmic, 
secreted, anchored to the cell wall, is also essential to influence the immunogenicity. For 
instance, the E7 antigen is a primary protein from human papillomavirus type-16. This 
antigen was expressed in Lactococcus lactis, and three cell locations of the antigen were 
evaluated, intracellular, secreted or anchored to the cell wall. After testing antigen 
immunogenicity by measuring their cellular immune responses, it has been found that the 
mice with cell wall anchored E7 antigen could stimulate higher level of cytokine responses 
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and induce highest immune responses. In contrast, the one with secreted E7 antigen have 
the lowest immune responses (Bermúdez Humarán & Bermudez-Humaran, 2004a). 
Although the results may be showed differently in other models of disease or infections, 
this result provided the excellent idea for future people to decide appropriate mucosal 
vaccine by presenting antigen in different locations.  
Lastly, level of antigen expression or amount of antigen uptake is also significant for 
immune responses in particular studies. Evidence from existing literature has indicated 
that more doses of antigen could boost higher antibody response in intragastric route. For 
example, different level expression of TTFC from L. lactis has been evaluated by antibody 
response. They found that a larger number of antibodies were triggered with increasing 
amount of TTFC (Wells & Mercenier, 2008). However, another study showed that the 
dosage may not play an essential role in immune response. Recombinant Lactococcus was 
designed to express C-repeated region (CRR) of M protein from Streptococcus pyogenes to 
against pharyngeal infection with S. pyogenes. This vaccine was introduced to mice nasally 
and serum IgG responses were examined. The result showed that the IgG response of a 
fourfold-higher dosage of LL-CRR is no significant difference with the response of the 
lower-dosage group (Mannam et al., 2004). Therefore, depending on the immunogenicity of 
antigen and delivery routes, a certain amount of oral vaccination could affect the immune 
response differently.   
Oral tolerance  
Immunologic tolerance is an important mechanism of the immune system. Effective 
vaccination can cause immune suppression when autoimmune diseases occur. An 
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advanced method of antigen-specific therapy is to induce peripheral T cell tolerance via 
oral or nasal administration of autoantigen, which promotes mucosal tolerance (Czerkinsky 
et al., 1999). 
Currently, autoantigens can be delivered in two different ways. The first one is to 
deliver purified autoantigen directly. The second method is using genetically modified 
organism expressing autoantigen and deliver recombinant microorganism through oral 
and nasal routes. The first approach has been well studied. Maassen has summarized oral 
tolerance induction in different models for various disease, such MS, EAE, rheumatoid 
arthritis, uveitis, thyroid disease, myasthenia gravis and type I diabetes by pure target 
antigens. Their results revealed that the autoimmune disease could be prevented and 
treated by oral or nasal administrated autoantigen in either human or animal model 
(Maassen et al., 1999).  
Since oral administration of soluble antigen showed an excellent immune suppression 
in autoimmune diseases, delivery systems have widely grown in the past decade. 
Recombinant lactobacilli expressing heterologous target autoantigen is the second 
approach for mucosal administration. The functional recombinant Lc. casei has been used 
to display tetanus toxin TTFC on the surface, and high-level expression of TTFC has been 
evaluated by parenteral immunization. By adjusting this recombinant Lc. casei, myelin 
protein also can be applied for oral tolerance induction (Maassen et al., 1999). 
Furthermore, live lactobacilli expressing guinea pig MBP72-85 significantly inhibited EAE 
after oral administration (Maassen, 2003). This method is not limited to EAE. It could also 
practice as a delivery system for other autoimmune diseases, such as rheumatoid arthritis 
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and uveitis. Several recombinant expressing autoantigen delivery systems have been 
studied but not been fully developed.  In table 2.1, oral administration systems with 
recombinant Lactobacillus spp. and Lactococcus spp. for several autoimmune diseases is 
summarized.  
Non–GMO Gram-positive oral delivery tool 
Gram-positive bacteria have a unique cell wall structure including thick peptidoglycan 
layer. Multiple components can attach to the peptidoglycan, such as teichoic acids, 
carbohydrates and protein. As mentioned above, many CWBD could recognize particular 
sequence or region of peptidoglycan and covalently and non-covalently bind to Gram-
positive bacteria, like LPxTG, LysM, SLH and SH3. Application of CWBD could be a new cell 
surface display system for oral administration. This approach seems more welcome than 
genetically modified organism (GMO). LAB is always interesting for displaying 
heterologous protein on their surface because of their GRAS status (Wessels et al., 2004), 
but GMO LAB could lead to problems and due to acceptability by regulatory agencies 
(Ribelles, Rodríguez, & Suárez, 2012). Therefore, binding heterologous protein to 
peptidoglycan results a non-GMO oral vaccine or oral tolerance systems.  
The LysM domain is an attractive CWBD. (Visweswaran et al., 2014) has reviewed that 
LysM –containing fusion protein is utilized for detection of bacteria and display of enzymes 
and antigen on the surface of Gram-positive bacteria. Most of the carriers are Lc. lactis and 
some Lactobacillus strains (Visweswaran et al., 2014). This could cause the direct contact 
between the antigen and immune system and increase immune response (Ribeiro et al., 
2002). For example, antigen of Enterovirus type 71 (VP1) was displayed on the surface of 
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Lc. lactis and recombinant Lc. lactis was orally administrated. Serum antibody response 
was stimulated in a mouse's model (Raha, Varma, Yusoff, Ross, & Foo, 2005; Varma, 2013). 
Moreover, Lb. acidophilus was also used as a carrier to display VP1 protein of chicken 
anemia virus. After orally administrating non-GMO Lb. acidophilus, serum antibody 
response, virus neutralization and amount of Th1 cytokines were observed (H. Moeini, 
Rahim, Omar, Shafee, & Yusoff, 2011). All of the results indicated non-GMO LAB could 
successfully suppress immune responses. 
2.5 Future prospects 
Lactobacilli have been admitted as an advanced tool for mucosal delivery. Depending 
on the diseases and its specific objectives (vaccination or tolerance), a suitable carrier/host 
strain, administration pathway, delivery system, cellular location of heterologous protein, 
dosage of protein and model of study are very essential for oral immunological research. In 
the future, comparing immune responses of an individual model with orally administrated 
live GMO lactobacilli and live non-GMO lactobacilli will be very exciting and may guide a 
direction for future vaccine design.  
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Figure 2.1 The pathogenesis of multiple sclerosis (Adapted from Murphy, 2012) 
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Table 2.1 Recombinant Lactobacilli and Lactococci expressing autoantigens in autoimmune 
diseases 
Autoimmune disease Vehicle Tolerogen Model References 
Multiple Sclerosis 
 
Lb. casei 
 
hMBP/ PLP 
 
 
(Maassen et al., 1999) 
 
EAE 
 
Lactobacilli 
 
hMBP 
gpMBP 
PLP 
 
Lewis rat 
 
(Maassen, 2003) 
 
Type 1 Diabetes  
 
Lc. Latis 
 
Pancreatic β cell 
HSP65-P277 
 
 
NOD 
mouse 
 
(Ma et al., 2014; Robert & 
Steidler, 2014) 
 
Cow's milk allergy 
 
Lc. latis 
 
Blg 
 
Mice 
 
(Adel Patient et al., 2005; 
Chatel et al., 2003) 
 
 
Celiac disease 
 
Lc. Latis 
 
Gliadin Peptide 
 
Mice 
 
(Huibregtse et al, 2009) 
 
 
Lb, lactobacillus 
Lc, Lactococcus  
hMBP, human myelin basic protein 
gpMBP, guinea pig myelin basic protein 
PLP, proteolipid protein peptide 
HSP65-P277, HSP65 with tandem repeats of P277 
Blg, bovine beta-lactoglobulin 
NOD mouse, Non-obese diabetic mouse  
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 RECOMBINANT LACTOBACILLI FOR SURFACE DISPLAY AND SECRETE OF MYELIN CHAPTER 3
ANTIGEN 
3.1 Introduction 
 Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system, That causes lesions in the brain, spinal cord and other areas of the body (Awad, 
1984). It has been shown that MS is an autoimmune disease mediated by CD4+ Th1 and 
Th17 inflammatory responses. Currently, several disease-modifying drugs have been made 
available for MS; such as IFN-β1a, IFN-β1b, mitoxantrone and natalizumab. Unfortunately, 
these drugs are not fully developed and have significant side effects including, flu-like 
symptoms, skin site reactions, transient headache fatigue and cardiotoxicity (reviewed by 
Castro Borrero et al., 2012b). Therefore, additional strategies to ameliorate MS are needed.  
The systemic administration of an autoantigen may be an effective treatment to induce 
antigen-specific T cell tolerance (reviewed by Liblau, Tisch, Bercovici, & McDevitt, 1997). 
Mucosal administration is a promising antigen-specific therapy to promote mucosal T-cell 
tolerance by anergy, deletion and active suppression (Maassen, 2003). When anergy 
(Karpus, Kennedy, Smith, & Miller, 1996) or deletion (Y. Chen, 1995) is the desired 
mechanisms, the autoantigen should be known. Our collaborator Dr. Mangalam and others 
have identified several critical epitopes of the MS-promoting autoantigens. These epitopes 
inculde the proteolipid protein (PLP) amino acids: 37-71, 89-154, 179-238, 264-277 and 
myelin-oligodendrocyte glycoprotein (MOG) amino acids: 30-150 and 181-203.  
Lactobacilli are Gram-positive lactic acid bacteria (LAB) which are commonly utilized 
in the food industry. Numerous lactobacillus strains are regarded as probiotics because 
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they provide immune-modulating and stimulating activities and contribute to health 
maintenance (Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME, 2009). Additionally, 
lactobacilli have been widely used as potential live vectors for heterologous protein 
delivery for oral vaccine, oral tolerance and pharmaceutical applications (Cortes Perez et 
al., 2005; H. Moeini et al., 2011; Xu et al., 2011). (Maassen, 2003) was the first group to 
develop a novel method of mucosal tolerance induction by administration of recombinant 
lactobacilli expressing a myelin basic protein (MBP) autoantigen in an animal model of MS, 
experimental autoimmune encephalomyelitis (EAE). Their conclusion revealed that the live 
recombinant lactobacilli expressing guinea pig MBP (gpMBP) or MBP72-85 were able to 
reduce the disease significantly when administered orally.  Furthermore, the system of oral 
delivery exercising LAB for MS is still under development. Since various lactobacilli have 
distinct properties, it is vital to select target lactobacilli strains carefully. We initially 
screened members of our lactobacilli culture collection to identify isolates that were 
amenable to our genetic tools. From that group, we identified three Lactobacilli that were 
good candidates for further study: L. acidophilus ATCC 4356 (LA4356), L. gasseri ATCC 
33323 (LG33323) and L. salivarius ATCC 11742 (LS11742). These strains were sent to our 
collaborators at the Mayo Clinic to test their inherent “probiotic” ability to suppress MS in a 
rodent model. We observed that the LS11742 had a strong suppressive effect and LG33323 
had a moderate suppressive effect; whereas, LA4356 had no suppressive effect. Therefore, 
LA4356, LG33323 and LS11742 were developed for recombinant autoantigen expression.  
The aim of this research was to determine the best strategy for heterologous 
expression in lactobacilli to suppress MS in rodents. We developed genetic tools for 
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heterologous protein expression, using two different strategies: 1) secreted autoantigen 
and 2) extracellular anchoring of the autoantigen. We targeted the two previously 
identified MS autoantigens, PLP and MOG. Following satisfactory expression and 
extracellular display, the recombinant lactobacilli will be evaluated for their suppressive 
potential in an MS rodent model. 
3.2 Material and method 
Microorganisms, plasmids and culture conditions 
 The bacterial strains and plasmids used in this study are listed in Table 3.1. 
Recombinant E. coli MC1061 and E. coli Top10 cells were incubated aerobically overnight 
at 37oC with shaking at 250 rpm in Luria-Bertani (LB) medium (Fisher Scientific, Fair 
Lawn, NJ) supplemented with 150 µg/ml of erythromycin (Fisher Scientific) or 50 µg/ml of 
ampicillin (Fisher Scientific); respectively. LA4356, LG33323 and LS11742 and other 
recombinant strains were grown in de Mann, Rogosa, Sharpe (MRS) broth (Difco, Sparks, 
MD) or on MRS agar plates and incubated overnight anaerobically (5% CO2, 5% H2 and 
90% N2).  When necessary, MRS broth or agar plates were supplemented with either 
2.5µg/ml or 5 µg/ml of erythromycin. 
DNA manipulation and plasmids construction 
Several genetic techniques were utilized in this study according to manufacturer’s 
procedures. The primers listed in Table 3.2 were designed using Clone Manager 9 (Sci-Ed 
Software, Raleigh, NC) and purchased from Integrated DNA Technologies (IDT, Coralville, 
IA). PCR was carried out using Econo Taq PLUS 2X Master Mix (Lucigen, Middleton, WI) 
according to manufacturer standard procedure. Amplified PCR fragments were purified 
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using DNA Clean and Concentrator Kit (Zymo Research, Orange, CA). PCR fragments were 
cloned into restriction-digested plasmids using the T4 DNA Ligase (New England Biolabs, 
Ipswich, MA). Plasmid DNA was purified from recombinant E. coli (MC1061 or Top10) 
using the QIAprep Spin Miniprep Kit (QIAGEN, Valencia, CA). Lactobacillus spp. was 
transformed by electroporation according to a previously described method (Francl, 
Hoeflinger, & Miller, 2012). Recombinant Lactobacillus strains were confirmed through the 
plasmid DNA isolation (O'Sullivan, 1993). All plasmid DNA sequences were confirmed by 
Sanger sequencing by the University of Illinois Urbana-Champaign Core Sequencing 
Facility. 
The design of expression vectors is described in Figure 3.1 (Plasmid could be found in 
Appendix A). Part A (secreted and anchor) was constructed to include the pgm promoter, 
an anchor signal (A1392) from the Mub gene and a secretion signal (S1709) from L. 
acidophilus NCFM and the Campylobacter jejuni FlpA gene. Similarly, Part B (secretion only) 
was constructed as Part A (S1709) except a stop codon was inserted to remove the anchor 
signal (A1392). Both Part A and Part B were modelled after (Kajikawa et al., 2012) and 
synthesized by GENEWIZ Inc. (South Plainfield, NJ).  Cloning was performed using pMJM8, 
a derivative plasmid from pGK12 with a multi-cloning site (MCS) from pBluescript 
containing an erythromycin resistance gene, at the restriction enzyme sites SacII and 
BamHI resulting in pFlpA_A and pFlpA_S, respectively (Berquist, 2014).  
The PLP, MOG and PLP/MOG epitopes were synthesized and cloned into pUC57 vector 
with XbaI and SpeI restriction sites by GENEWIZ Inc. to generate plasmids pPLP, pMOG and 
pP/M; respectively. The genes of PLP, MOG and PLP/MOG epitopes were generated in two 
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different methods for cloning. First, PLP, MOG and PLP/MOG genes were isolated from 
pPLP, pMOG and pP/M by enzyme digestion with the XbaI and SpeI restriction enzyme 
sites. Then three inserts replaced the XbaI-SpeI spanning fragments (FlpA) in pFlpA_A that 
obtained pPLP_A, pMOG_A and pP/M_A.     
Secondly, The PLP epitope was isolated from vector pPLP by PCR amplification using 
the primer set LZ_PLP F-XbaI and LZ_PLP R-BamHI with XbaI and BamHI sites. The MOG 
epitope was obtained from vector pMOG by PCR amplification using the primer set LZ_MOG 
F-XbaI and LZ_MOG R-BamHI with XbaI and BamHI sites. The PLP/MOG epitopes were 
isolated from the vector pP/M by PCR amplification using the primer set LZ_PLP F-XbaI and 
LZ_MOG R-BamHI with XbaI and BamHI sites. The resulting PLP, MOG and PLP/MOG 
amplicons were enzyme digested and ligated into pFlpA_S in place of the FlpA fragment 
using the XbaI-BamHI restriction enzymes. The resulting plasmids are listed in Table 3.1. 
All plasmids were first transformed into E. coli MC1061 and purified. Subsequently, all PLP, 
MOG, PLP/MOG plasmids were transformed into LA4356, LG33323, and LS11741. 
Protein validation and SDS-PAGE PROTEIN GEL/ WESTERN BLOT 
For expression analysis, the recombinant lactobacilli were grown to mid-log phase in 
MRS broth and cells were pelleted by centrifugation at 4000 rpm. Each bacterial pellet was 
resuspended in 20 μL per unit of optical density at 600 nm (OD600) with Tris-EDTA 
containing 3 mg/mL lysozyme, 25 U/mL DNase I, and 1x complete protease inhibitor 
cocktail (Roche, USA). After incubation for 1 h at 37°C, one part volume of 2 x reducing 
sample buffer was added, the samples were lysed by heating to 100°C for 5 min and 
centrifuged at 14,000 rpm for 1 min. The soluble protein fraction was separated from the 
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bacterial lysate by SDS-PAGE (Stoeker et al., 2011). In order to analyze the secreted protein 
fraction in the cellular supernatant, 5 mL of mid-log phase recombinant lactobacilli were 
harvest by centrifugation at 4000 rpm at 4oC. Approximately, 10 mg of sodium 
deoxycholate (Fisher) was added, mixed by vortex and incubated at 4oC for 30 min. The 
proteins were precipitated overnight at 4oC by addition of 300 μL of chilled 100% (w/v) 
trichloroacetic acid (TCA, Fisher). Proteins were recovered by centrifugation at 4000 rpm 
for 10 min at 4oC followed by washing twice with 2 mL of chilled acetone. Finally, pellets 
were dried at room temperature and re-solubilized by sonication in 40 μL of 1x Laemmli 
buffer (Sánchez, Chaignepain, Schmitter, & Urdaci, 2009).  
Protein presence and size were confirmed by western blotting at the Mayo Clinic. The 
western blot protocol was provided by our collaborator Dr. Mangalam. Briefly, the SDS-
PAGE gel was run at 7 mA constant current without cooling, and the blot apparatus was set 
up with the dark grid down and blotted for 45 min at 90 volts. The membrane was washed 
in 18 megohm water for a few minutes, and then blocked for 20 s with 4% BSA 1X TBS. 
About 1 mg/ml anti phoshotyrosine antibody of 30 ml mixture (2% BSA, 1% Tween-20) 
was added in the blot and incubate at room temperature with shaking. After that, the 
membrane was washed 3 times with 0.2% Tween-20 in 1X TBS. Lately, 3 mL of goat anti 
mouse HRP antibody in 30 mL of 0.2% Tween-20 in 1XTBS was added in the blot and 
gently shake for 45 min at room temperature. After washing, the membrane was exposed 
to film for 20 min.  
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3.3 Results  
Construction of anchored and secreted protein vectors 
The expression vectors pPLP_A, pMOG_A and pP/M_A containing both S1709 and 
A1392 signals were constructed with the PLP, MOG or PLP/MOG epitopes (Table 3.1 and 
Figure 3.1). Successful ligations were sequence confirmed using the primers AB_p13F-XbaI 
and AB_p13R-Spel. Unfortunately, all of the transformants of pPLP_A, pMOG_A and pP/M_A 
had incorrect insertion configurations.  
In the meantime the expression vectors pPLP_S, pMOG_S and pP/M_S containing only 
the S1709 signal were constructed with the PLP, MOG or PLP/MOG epitopes. Successful 
ligations were sequence confirmed using the primers AB_p13F-XbaI and AB_p14R-BamHI.  
The expression vectors pPLP_S, pMOG_S and pP/M_S were confirmed to harbor PCR 
amplicons of 717-bp, 621-bp and 1146-bp; respectively (Figure 3.2).  Sequencing results 
confirmed that the PLP, MOG and PLP/MOG epitopes were successfully ligated in place of 
the FlpA fragment in the pFlpA_S vector. In addition, the expression vectors pPLP_S, 
pMOG_S and pP/M_S have been isolated from Lactobacillus strains. Thus far, we are 
confident that LG33323 contains pMOG_S (MJM280) and pP/M_S (MJM281), LA4356 
contains pPLP_S (MJM285), pMOG_S (MJM286), pP/M_S (MJM287) and LS11741 contains 
pPLP_S (MJM291).  
Since successful transformants were obtained using the expression vectors containing 
only the S1709 signal, we attempted to the A1392 signal directly into pPLP_S, pMOG_S and 
pP/M_S using the SpeI and BamHI restriction sites.  Unfortunately, this proved futile as 
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mutants were consistently found in the anchor signal in all sequenced transformants. 
Based on these results we decided to continue exploring the secreted protein only.  
Expression of the secreted proteins containing of the PLP, MOG and PLP/MOG epitopes 
Since LA4356 was successfully transformed with all three epitopes, it was evaluated 
for its ability to express the secreted protein (Table 3.1). Protein expression was confirmed 
using cellular lysates and the cell-free supernatant prepared from the LA4356 containing 
the pPLP_S, pMOG_S and pP/M_S. Production of the target proteins were confirmed by 
Western blotting (Figure 3.3).  The PLP epitope was detected in LA4356 containing pPLP_S 
cellular lysate. The estimated molecular mass of the PLP epitopes is approximately 27.4 
kDa which is consistent with our results.  Unfortunately, PLP or MOG was not detected in 
the LA4356 strains containing pMOG_S and pP/M_S. Furthermore, secreted protein 
fractions were unable to isolate from the cellular supernatant, which may be caused by the 
contamination of other membrane proteins. The smear was observed on the SDS-PAGE gel.   
3.4 Discussion  
Lactobacilli have the ability to attach and colonize at certain regions of intestine, which 
could stimulate both specific and non-specific immune response (Blomberg, 1993; E. E. 
Vaughan, 1999). Therefore, Lactobacilli is used as live delivery carrier for oral 
immunization against different infections and diseases, such as Salmonella infection 
(Rahbarizadeh et al., 2011) and anthrax (Zegers et al., 1999b). Individual Lactobacillus 
strains have different effect in oral tolerance induction. Our previous study shows that L. 
gasseri ATCC 33323 had a moderate suppressing effect on MS; L. salivarius ATCC 11742 
had a strong suppressing effect on MS whereas L. acidophilus ATCC 4356 had no effect on 
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MS. Different suppressing effects between these three strains may be caused by variability 
in pathogen associated molecular patterns (PAMPs) such as peptidoglycan, cell wall 
polysaccharides, lipoproteins, and lipoteichoic acid (LTA) anchored in the cytoplasmic 
member (van Baarlen, Wells, & Kleerebezem, 2013). From molecular cloning perspective, 
all three strains were selected as expression host. Also, it was unknown what inherent 
property of the lactobacilli would work best with the autoantigens. 
The number of studies on oral immunization of MS disease is very limited. Therefore, 
our strategy to promote tolerance of MS disease with autoantigen expression in lactobacilli 
using both secretion and anchored protein models. In previous studies, the 
immunogenicity of an antigen was shown to be strongly influenced by its final cellular 
location (cytoplasmic, secreted, or anchored to cell wall).  Since the anchoring of an antigen 
to the extracellular surface showed the highest antigen immunogenicity, we chose to design 
an anchored protein expression vector as well as a secreted protein expression vector 
(Bermúdez Humarán & Bermudez-Humaran, 2004b; Norton, 1996b). In this study, three 
protein expression vectors were constructed to either secrete or secrete and extracellularly 
anchor the PLP, MOG, PLP/MOG epitopes. Since anchored vector construction was 
unsuccessful, alternative cell wall anchored strategy is necessary.  
The PLP and MOG epitopes were chosen to be expressed independently or in 
combination. It is important to determine which heterologous protein (single or combined) 
has desired impact on the immune response. The previous study demonstrated that a 
heterogeneous antigen preparation like myelin is less effective than single antigen (MBP) 
in term of inducing tolerance (Benson, 1999). Possibly, there are immune response 
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differences among various heterologous proteins, but more studies are needed. A 
secondary outcome of this study was to determine which heterologous protein (PLP, MOG 
or PLP/MOG) has the highest suppressive effect on MS. 
Unfortunately, expression vectors pPLP_A, pMOG_A and pP/M_A were unable to be 
isolated successfully. Based on the sequencing results, a majority of transformants had 
incorrect insertion configuration, which was caused by the same sticky ends, CTAG of 
enzymes XbaI (TCTAGA) and SpeI (ACTAGT). Moreover, within the minor amount of 
correct insertion transformants, mutants were found in both the epitope sequence and the 
anchor sequence on various locations in different duplications. Our conclusion is that 
constructs are lethal to E. coli and preventing our successful cloning. Interestingly, we have 
been able to construct pFlpA_A indicating that a different heterologous protein (FlpA) with 
an anchor signal can be successfully expressed in E. coli so there is something uniquely 
problematic with PLP and MOG (Berquist, 2014). Additionally, pP/M_S was unable to 
transform into LG33323; pMOG_S and pP/M_S were unable to transform into LS11741 as 
well. Strong constitutive promoter, pgm, may lead these unexpected mutations and failing 
transformation. High level of constitutive expression can be lethal to the host cell, inhibit 
growth, loss of the expression vector and recombinant DNA structural instability (Hanniffy 
et al., 2004b; Makrides, 1996). 
Soluble bacterial lysates from recombinant LA 4356 (MJM285, MJM286, MJM287) were 
sent out for western blot. Expected sizes of MOG epitopes (24.6kDa) and PLP/MOG 
(44kDa) were not shown at the gel in Figure 3.3. It could be caused by multiple reasons. 
First, as mentioned above, MOG epitopes and PLP/MOG epitopes may not be expressed 
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successfully by LA 4356 due to strong constitutive promoter (Makrides 1996). Second, 
MOG and PLP/MOG may be in an insoluble form and have been excluded in the samples. 
Furthermore, the antibodies for MOG and PLP/MOG may be another reason for these 
proteins were not detected.  
3.5 Conclusion 
In this study, PLP epitope is successfully detected from LA4356 cell lysate, which 
indicates that L. acidophilus may be a candidate for PLP expression. Further research is 
necessary to design a vector with a functional anchored signal. While this study 
demonstrated protein expression of the PLP epitope in L. acidophilus, the animal data is 
critical to evaluate its potential as a therapeutic for MS. Once the animal experiments are 
complete, we can reevaluate our approach. For example, we will know which lactobacilli 
strain provides the optimal results based on our application. Efficacy of this study may be 
further improved by optimizing autoantigen expression level, such as replacement of the 
pgm promoter to a low expression promoter to test how protein expression levels 
influences the in vivo effects.  At this time, we have abandoned anchored strategy and 
developed alternate strategies for cell surface localization (see chapter 4).  
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Table 3.1 Bacterial strains and plasmids 
Bacterial strain MJM Plasmid Description of plasmid Source  
E.coli Top10 NA Cloning host Invitrogen 
 
259 pPLP 
ApR, pUC57 backbone, PLP 
inserted 
This Study  
 
260 pMOG 
ApR, pUC57 backbone, MOG 
inserted 
This Study  
 
261 pP/M 
ApR, pUC57 backbone, 
PLP/MOG inserted 
This Study  
E. coli MC1061 NA Cloning host Klaenhammer  
 
106 pMJM8 EmR Miller Lab 
 
256 pFlpA_A 
EmR, pMJM8 backbone, FlpA 
with secretion and anchor 
signals 
Miller Lab 
 
257 pFlpA_S 
EmR, pMJM8 backbone, FlpA 
with secretion and stop 
signals 
Miller Lab 
 
262 pPLP_A* 
EmR, pMJM13 backbone, PLP 
inserted  
This Study  
 
263 pMOG_A* 
EmR, pMJM13 backbone, 
MOG inserted  
This Study  
 
264 pP/M_A* 
EmR, pMJM13 backbone, 
PLP/MOG inserted  
This Study  
 
265 pPLP_S 
EmR, pMJM14 backbone, PLP 
inserted  
This Study  
 
266 pMOG_S 
EmR, pMJM14 backbone, 
MOG inserted  
This Study  
 
267 pP/M_S 
EmR, pMJM14 backbone, 
PLP/MOG inserted  
This Study  
L. gasseri ATCC 33323 NA Expression host Miller Lab 
 
276 pPLP_A * 
EmR, pMJM13 backbone, PLP 
inserted  
This Study  
 
277 pMOG_A * 
EmR, pMJM13 backbone, 
MOG inserted  
This Study  
 
278 pP/M_A * 
EmR, pMJM13 backbone, 
PLP/MOG inserted  
This Study  
 
279 pPLP_S * 
EmR, pMJM14 backbone, PLP 
inserted  
This Study  
 
280 pMOG_S 
EmR, pMJM14 backbone, 
MOG inserted  
This Study  
 
281 pP/M_S 
EmR, pMJM14 backbone, 
PLP/MOG inserted  
This Study  
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Table 3.1(cont.) 
L.acidophilus  
ATCC 4356 
NA Expression host Miller Lab 
 
282 pPLP_A * 
EmR, pMJM13 backbone, PLP 
inserted  
This Study  
 
283 pMOG_A * 
EmR, pMJM13 backbone, 
MOG inserted  
This Study  
 
284 pP/M_A * 
EmR, pMJM13 backbone, 
PLP/MOG inserted  
This Study  
 
285 pPLP_S 
EmR, pMJM14 backbone, PLP 
inserted  
This Study  
 
286 pMOG_S 
EmR, pMJM14 backbone, 
MOG inserted  
This Study  
 
287 pP/M_S 
EmR, pMJM14 backbone, 
PLP/MOG inserted  
This Study  
L. salivarius  
ATCC 11741 
NA Expression host Miller Lab 
 
288 pPLP_A * 
EmR, pMJM13 backbone, PLP 
inserted  
This Study  
 
289 pMOG_A * 
EmR, pMJM13 backbone, 
MOG inserted  
This Study  
 
290 pP/M_A * 
EmR, pMJM13 backbone, 
PLP/MOG inserted  
This Study  
 
291 pPLP_S 
EmR, pMJM14 backbone, PLP 
inserted  
This Study  
 
292 pMOG_S * 
EmR, pMJM14 backbone, 
MOG inserted  
This Study  
  
293 pP/M_S * 
EmR, pMJM14 backbone, 
PLP/MOG inserted  
This Study  
* In progress, remains to be constructed; EmR, Erythromycin resistant 
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Table 3.2 Primers used in this study 
Primers Sequence 
AB_p13F-XbaI CTGGTTTGGCTACAGTATTC  
AB_p13R-SpeI CCTAAGCCAGAGAACACT  
AB_p14R-BamHI CTTTAGTGAGGGTTAATTTCGA 
LZ_PLP F-XbaI CTAGTCTAGACATGAGGCTTTGACA 
LZ_PLP R-BamHl ACGCGGATCCGAACTTTGTTCCACGACCCAT 
LZ_MOG F-XbaI CTAGTCTAGAGGTCAGTTCCGTGTA 
LZ_MOG R-BamHl ACGCGGATCCTCTCAAGAAGTGAGGGTCGAA 
LZ_A1392 F-BamHl ACGCGGATCCACAGTTACAGTTACTTACAC 
LZ_A1392 R-Apal CTAGGGGCCCTTATTTGTCCTCCTTTCTACG 
LZ_pMJM20/21 F-BamHI GTGGAAAGTTGCGTGCAGAG 
LZ_pMJM19 F-BamHI ACTTCGCAGTATTGAAGTTG 
LZ_pMJM19 R-ApaI CAGCTATGACCATGATTACG 
Restriction enzyme sites are underlined   
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Figure 3.1 Gene map of an expression cassette for PLP, MOG and PLP/MOG epitopes. 
FlpADII gene was replaced by target epitopes in Part A and obtains pPLP_A, pMOG_A and 
pP/M_A. FlpADII gene was replaced by target epitopes in Part B and obtains pPLP_S, 
pMOG_S and pP/M_S. Ppgm,  promoter region of pgm gene from L. acidophilus NCFM; R, 
region encoding ribosome binding site of Mub from L. acidophilus NCFM (LBA1709 or 
LBA1392); S1709, region encoding the signal sequence of Mub (LBA1709 or LBA 1392); 
A1709/A1392, region encoding the anchor region of Mub (LBA1709 or LBA 1392).  
  
 
  
 
   
 
 
 
 
  
Plasmid  Target protein Size  Protein weight 
pPLP_A PLP 537 bp 41.5 kDa 
pMOG_A MOG 441 bp 38.7 kDa 
pP/M_A PLP/MOG 966 bp 58.0 kDa 
Plasmid  Target protein Size  Protein weight 
pPLP_S PLP 537 bp 27.4 kDa 
pMOG_S MOG 441 bp 24.6 kDa 
pP/M_S PLP/MOG 966 bp 44.0 kDa 
R S1709 A1392 FlpA DII Ppgm 
 
 SacII                       XbaI       SpeI       BamHI      
Part A 
SacII                       XbaI      BamHI      
R S1709 STOP FlpA DII Ppgm 
 
Part B 
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Figure 3.2 PCR verification of the inserts. Primers were designed that flanked the insert. 
Gels show PCR products for screening pPLP_S, pMOG_S and pP/M_S. All negative are FlpA 
amplicons 457 bp, which means auto antigens were failed to clone into pFlpA_S. Gel#1, 
positive is PLP amplicon 717 bp (pPLP_S). Gel#2, positive is MOG amplicon 621bp 
(pMOG_S). Gel#3, positive is PLP/MOG amplicon 1146bp (pP/M_S). In all three cases, the 
transformants that had the correct size amplicon were sequence verified. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 -        +     ladder  -          +      ladder +        -     ladder 
1000bp 1000bp 1000bp 
500bp 500bp 500bp 
    Gel #1                                                      Gel #2                                           Gel #3 
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Figure 3.3 Soluble bacterial lysates from recombinant LA 4356. MJM285 expressing PLP 
epitopes (lane 1); MJM286 expressing MOG epitopes (lane 2); MJM287 expressing 
PLP/MOG epitopes (lane 3) were separated by electrophoresis on polyacrylamide gel. 
(Adapted from Dr. Ashutosh Mangalam, Mayo Clinic)                       
  
   1          2        3      
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 CELL WALL BINDING OF HETEROLOGOUS PROTEIN TO THE EXTERIOR SURFACE CHAPTER 4
OF LACTOBACILLUS SPP. 
4.1 Introduction 
Lactic Acid Bacteria (LAB) including Lactobacillus spp. are defined as a group of gram-
positive, facultative anaerobic, fermentative bacteria (Makarova et al., 2006). Many 
Lactobacillus spp. are known as starter cultures for fermented food, such as yogurt, cheese, 
fermented milk, sausage, alcoholic beverage and other fermented foods. The natural habits 
of Lactobacillus spp. are not only in food fermentation environment but also in oral cavity 
and gastrointestinal tracts of human and animals (E. Vaughan, de Vries, Zoetendal, Ben 
Amor, Akkermans, & de Vos, 2002b). In addition, they are generally recognized as safe 
(GRAS) and some of them are considered as ‘probiotics’ strains, which provide health 
benefits to the host. 
 Over the past decade, food grade LAB, especially lactococci and lactobacilli, have 
been used as potential live vectors for heterologous protein delivery for oral vaccine, oral 
tolerance and pharmaceutical applications (Cortes Perez et al., 2005; Moeini, Hassan 
Rahim, Raha Omar, Abdul Shafee,Norazizah Yusoff, Khatijah, 2011; Xu et al., 2011). 
Previously, research had focused on the expression and anchoring of heterologous proteins 
to the extracellular surface using recombinant LAB. For example, the recombinant 
Lactococcus lactis expressing the envelop protein of HIV induces immune response and 
could be used as an HIV vaccine (Xin et al., 2003). However, this results a genetically 
modified (GM) lactococci. Therefore, researchers have begun developing alternative 
mucosal immunization strategies.  
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Several methods have been proposed that bind purified exogenous proteins onto the 
extracellular surface of non-GM LAB. The selection of which methods to use is dependent 
on the chosen heterologous protein. Surface-associated proteins can be bound to the 
extracellular surface either by covalent cell-wall binding domains (CWBD) or non-covalent 
CWBD. Covalent CWBDs can be a single hydrophobic N- or C-terminal domain, lipid-
anchored or LPxTG cell-wall anchor; whereas non-covalent CWBD can include LysM 
domains, choline-binding domains, putative peptidoglycan-binding domains, S-layer 
protein domains, WxL domains and SH3 (Kleerebezem et al., 2010). Several studies have 
utilized non-covalent CWBD and have shown promising results.  Particularly, the LysM 
(Pfam PF01476) domain is a commonly utilized non-covalent CWBD, which consists of 
repeat units of a small LysM motif. This domain is usually found in many extracellular 
enzymes and has the capability to anchor proteins in the peptidoglycan (PG) layer of Gram-
positive bacteria (Buist et al., 2008). Currently, widespread utilization of the LysM domain 
has been used for detection of bacteria and display of enzymes and/or proteins on the 
extracellular surface of Gram-positive bacteria (Visweswaran et al., 2014). Another method 
uses the autolysin, N-Acetylmuraminidase (AcmA), produced by Lactococcus lactis. AcmA is 
responsible for cell separation and cell lysis during the stationary phase of growth (Buist, 
1995). The AcmA gene of L. lactis MG1363 consists of three domains: an N-terminal signal 
sequence, an active domain and a C-terminal membrane anchor.  Interestingly, the C-
terminal membrane anchor possesses three repeated regions of the LysM motif (Buist, 
1995). The CWBD of AcmA has strong binding capacity of proteins onto the surface of 
naturally occurring lactococcal strains and Lactobacillus spp. (Raha et al., 2005; Varma, 
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2013). Another popular non-covalent CWBD is the eukaryotic SH3 domain. This domain is 
able to target and anchor proteins to the PG layer by recognition of specific sequences 
within the cross-linking peptide bridges (Baba, 1996).  
 In this study, three non-covalent CWBD were selected including L. gasseri ATCC 
33323 LysM domain-containing protein (LysM; NCBI Ref. YP_814716.1); L. gasseri ATCC 
33323 Lysozyme M1, Bacterial SH3 domain (SH3; NCBI Ref. YP_814010.0); and C-terminal 
membrane anchor domain of L. lactis subsp. cremoris MG1363 AcmA protein (AcmA; 
GenBank CAL96887.1). The L. gasseri LysM domain and L. gasseri Lysozyme SH3 domains 
were predicted CWBD (Kleerebezem et al., 2010) based on the integrated subcellular 
location prediction pipeline provided by LocateP (Zhou et al., 2008).  Here, we report on 
the expression of fusion proteins (Green fluorescent protein fused with cell wall binding 
anchor protein) from a recombinant Escherichia coli. Additionally, we describe a novel 
display method of these three CWBD with the target epitope (PLP/MOG) on the cell surface 
of L. acidophilus ATCC 4356 (LA4356), L. gasseri ATCC 33323 (LG33323), and L. salivarius 
ATCC 11741 (LS11741). 
4.2 Materials and methods 
Microorganisms, plasmids and culture condition 
The bacteria strains and plasmids used in this study are listed in Table 4.1. E.coli Top 
10 was purchased (Invitrogen, Carlsbad, CA) and used as the cloning host. E.coli BL21 
(DE3) plysS strains (Invitrogen) was used as the E.coli expression host. The cloning vector 
pUC19 (Invitrogen) was used to clone all synthesized fragments; while pRSETB 
(Invitrogen) was used as a cloning and expression vector. Recombinant E.coli strains were 
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incubated overnight in LB medium (Becton, Dickenson, Franklin Lakes, New Jersey) 
supplemented with antibiotics (E. coli Top 10: 100 µg/ml of Ampicillin [Fisher, Hampton, 
NH], E. coli BL21 (DE3): 50 µg/ml of Ampicillin and 35 µg/ml of Chloramphenicol [Fisher]) 
at 37°C aerobically with shaking at 250 rpm. L. gasseri ATCC 33323, L. acidophilus ATCC 
4356, and L. salivarius ATCC 11741 were incubated overnight in MRS broth (Becton, 
Dickenson) at 37°C anaerobically (5% CO2, 5% H2 and 90% N2 atmosphere).   
Construction of Plasmid pUC19 and transformation into competent E. coli 
Three non-covalent CWBD, LysM, SH3 and AcmA, were synthesized as gBlocks® Gene 
Fragments with XhoI and HindIII restriction sites by Integrated DNA Technologies (IDT, 
Coralville, IA). The PLP/MOG peptide was also synthesized as a gBlocks® Gene Fragment 
with BamHI and XhoI restriction sites. The above CWBD and PLP/MOG peptide were cloned 
into the pUC19 digested with the blunt end restriction enzyme SmaI (New England Biolabs, 
Ipswich, MA) to generate plasmids pUC-PLP/MOG, pUC-LysM, pUC-SH3 and pUC-AcmA 
(Table 4.1). Each plasmid was transformed into E.coli Top10 competent cells and screened 
using the blue/white screening method. The ligations were confirmed by UIUC core 
sequencing facility by universal primers M13For-21and M13Rev-24 (Table 4.2).   
Generation and cell binding of fused green fluorescent protein or PLP/MOG 
The enhanced green fluorescent protein (EGFP) gene was isolated from the vector 
pEGFP-N1 (Invitrogen) by PCR amplification using forward primer LZ_EGFP_F with BamHI 
and the reverse primer LZ_EGFP R-XhoI with XhoI site. This specific EGFP gene was chosen 
because it contains a mutant of the wild-type GFP gene allowing for greater expression in 
mammalian cells and brighter green fluorescence. The EGFP amplicon was digested with 
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BamHI and XhoI restriction enzymes. The three CWBD were obtained by enzyme digestion 
from pUC-PLP/MOG, pUC-LysM, pUC-SH3 and pUC-AcmA with XhoI and HindIII restriction 
sites. The resulting fragments were cloned into the vector pRSETB digested with BamHI 
and HindIII enzymes to get a series of plasmids (pEGFP-LysM, pEGFP-SH3 and pEGFP-
AcmA; Table 4.1).  The resulting plasmids contained EGFP gene and each individual CWBD. 
An additional step exchanged EGFP with PLP/MOG and generated the plasmids pEGFP-
LysM, pEGFP-SH3 and pEGFP-AcmA with the same restriction sites to get another series of 
plasmids (pPLP/MOG-LysM, pPLP/MOG-SH3, pPLP/MOG-AcmA; Table 4.1). The plasmids 
obtained were transformed into E. coli Top10 and sequenced using the primers 
LZ_pRSETB_F and LZ_pRSETB_R to ensure that the ligations were successful. Finally, each 
plasmid was transformed into E. coli BL21 (DE3) pLysS competent cells for protein 
expression. All PCRs were carried out using Econo Taq DNA Polymerase (Lucigen, 
Middleton, WI), and the oligonucleotides used are listed in Table 4.2.  
Protein expression in E. coli BL 21(DE3) plysS  
The recombinant E. coli BL21 (DE3) plysS cells were cultured as outlined previously. 
The overnight cultures were subcultured into a fresh 10 mL of LB medium containing 
ampicillin (50 𝜇g/mL) and chloramphenicol (35 𝜇g/mL) and incubated until mid-log phase 
(~OD600nm = 0.6) at 30 °C before being induced with 0.1 mM isopropyl-𝛽-D-
thiogalactopyranoside (IPTG, MP Biomedicals, Santa, CA) for 4 to 6 h. Cells were harvested 
and resuspended in 3 ml of phosphate-buffered saline (PBS). Then the cells were disrupted 
by sonication at 70 W for five cycles (one consists of 15 s sonication with intermission of 30 
s), with interval cooling on ice. 20 µL of clear lysates were centrifuged at 15,000 rpm for 30 
53 
 
min at 4oC to separate soluble and insoluble protein. 20 µL of 2X reducing sample buffer 
(BIORAD, Hercules, CA) was added into soluble cell lysate and insoluble cell pellet was 
resuspended in 40 µL of 2X reducing sample buffer (BIORAD) prior to boiling at 95°C for 10 
min followed by centrifugation at 10,000 g. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE, BIORAD) was performed according to Laemmli (1970), using 
10%–12.5% (w/v) polyacrylamide gels. An aliquot of 25 𝜇L of total protein, soluble protein 
and insoluble protein were loaded onto the gel (Figure 4.2).  
Purification of the fusion proteins and binding to lactobacilli 
300 mL of the cell culture were harvest after 6 h induction with IPTG. The cell were 
resuspended in 10 mL of lysis buffer (pH 8.0) containing 50 mM Tris-HCl, 300 mM NaCl, 
10% glycerol, 2mM Dithiothreitol, 20 mM imidazole and 0.1% Triton X-100, followed by 
sonication at a power output of 70 W for 5 min (750 W Ultrasonic Processor, SONICS, 
Milpitas, CA), with interval cooling on ice. The crude cell lysate was centrifuged at 13,000×g 
at 4°C for 20 min. Then the supernatant containing soluble protein was loaded into a Ni2+ 
affinity column (Clonetech, Mountain View, CA). The mixture of soluble proteins and the 
Ni2+ beads were incubate at 4°C overnight with gentle agitation, and then washed five times 
with washing buffer (50 mM Tris-HCl, 300 mM NaCl, 10% glycerol, 2mM Dithiothreitol, 40 
mM imidazole, 0.1% Triton X-100, pH 8.0). Finally, the proteins were eluted by 1.5 mL of 
elution buffer (50 mM Tris-HCl, 300 mM NaCl, 10% glycerol, 2mM Dithiothreitol, 300 mM 
imidazole, 0.1% Triton X-100, pH 6.0).   
Lactobacilli preparation and binding method have been described previously (Moeini, 
2011). The culture of LA4356, LG33323 and LS11741 were grown to mid-log phase in MRS 
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broth (OD600 of 0.5–0.7), and harvested at 13,000×g for 5 min. The cells were resuspended 
in 500μl of PBS, and then mixed with 100 μl of the purified proteins followed by 4 h of 
incubation at 30°C. The cells were precipitated at 13,000×g for 1 min and then washed with 
PBS five times. The binding was analyzed by immunofluorescence microscopy (Zeiss 
Axiovert 200M, Jena, Germany) at core facilities of the Institute for Genomic Biology at the 
University of Illinois at Urbana-Champaign.  
4.3 Results  
Construction of the recombinant plasmids 
The pRSET vectors are pUC-derived expression vector designed for high-level protein 
expression and purification from cloned genes in E. coli. The plasmid contains the strong T7 
promoter, initiation ATG, N-terminal 6xHis tag, N-terminal XpressTM epitope tag, 
Enterokinase cleavage site, multiple cloning site, T7 terminator and Ampicillin resistance 
gene. The strong T7 promoter was induced by the addition of IPTG. PCR confirmed that 
pEGFP-LysM, pEGFP-SH3 and pEGFP-AcmA harbored fragments of 982-bp, 1534-bp and 
1426-bp; respectively. Sequencing results showed that EGFP was successfully cloned in 
frame with three different CWBDs in the pRSETB vector. The pRSETB construct maps are 
shown in Figures 4.1A. Transformed cells were selected on ampicillin plates after overnight 
incubation. Recombinant plasmids were then transformed into E.coli BL21 (DE3) plysS 
cells.   
The PLP/MOG peptide was obtained by enzyme digestion of pUC-PLP/MOG with 
BamHI and XhoI restriction enzymes and followed by Gel Extraction Kits (QIAGEN, Hilden, 
Germany). The pEGFP-LysM, pEGFP-SH3 and pEGFP-AcmA were treated with the same 
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restriction enzymes to generate compatible ligation sites. The pRSETB construct maps for 
pPLP/MOG-LysM, pPLP/MOG-SH3 and pPLP/MOG-AcmA are shown in Figures 4.1. 
Transformed cells were selected on ampicillin plates after overnight incubation. 
Recombinant plasmids were then transformed into E.coli BL21 (DE3) plysS cells.  
Expression of EGFP fusion protein in E.coli BL21 (DE3) plysS 
The expression of all EGFP and EGFP fusion protein (EGFP_LysM, EGFP_SH3, 
EGFP_AcmA) was detected by SDS-PAGE from the crude protein extraction of pRSETB, 
pEGFP, pEGFP-LysM, pEGFP-SH3 and pEGFP-AcmA transformed E.coli BL21 (DE3) plysS 
(Figure 4.2). In the protein extracts of E. coli BL21 (DE3) plysS, pRSETB was used as a 
negative control, which did not express any protein. EGFP (27KDa), EGFP_LysM (34KDa) 
and EGFP_SH3 (54KDa) fragments were observed in total (T), soluble (S) and insoluble (I) 
crude protein extractions, the size being approximately the same as the calculated size. 
However, majority of EGFP_AcmA (49KDa) was observed in insoluble protein extraction. It 
indicated that EGFP_AcmA, which was induced by the method above, was made insoluble 
form and cannot be used as cell surface associate binding protein.  
Binding of purified fusion proteins on the cell wall surface of Lactobacilli 
EGFP, EGFP_LysM and EGFP_SH3 were purified on Ni2+ affinity columns, but we have 
problem for EGFP_LysM protein purification. At this time, we may only focus on SH3 
domain. EGFP_SH3 protein mixed with LA4356, LG33323 and LS11741 as described above. 
Immunofluorescence microscopy verified the binding of EGFP_SH3 on the cell wall surface. 
These three lactobacilli cells exhibited bright fluorescence on the cell surface (Figure 4.3), 
which indicated the presence of EGFP_SH3 on the cell wall surface. Moreover, more 
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fluorescence was observed on the surface of LA4356 and LG3332, which means EGFP_SH3 
had higher binding efficiency to these two strains. In contrast, EGFP_SH3 has lower binding 
efficiency to LS11741. The control bacterial cell showed no fluorescence.  
4.4 Discussion  
Bacterial surface display has been widely studied and used for vaccine delivery. 
Lactobacillus spp. is gram-positive bacteria that could potentially be developed as oral 
delivery vehicle, because of their GRAS status (Wessels et al., 2004). Currently, numbers of 
studies have been conducted to display heterologous proteins on the surface of lactobacilli. 
Expression system in lactobacilli could present heterologous protein in three cellular 
locations, intracellular, secreted and anchored. Cell wall anchored protein has shown to be 
the most efficiency to induce specific immune responses compared to cytoplasmic or 
secreted protein (Reveneau, Geoffroy, Locht, Chagnaud, & Mercenier, 2002). However, 
translocation is always a limited step, which could control by the level of sortase and 
transpeptidase (Dieye et al., 2003b). Thus, it is hard to control number of protein on the 
cell wall and level of expression. Moreover, as we found out in the last experiment (chapter 
3), it is also difficult for plasmid transformation or protein expression in lactobacilli. Based 
on all these defects of protein expression above, CWBD display system of heterologous 
protein seems more welcome than expression system in lactobacilli. We can avoid the 
cloning and expression problems. Moreover, recombinant lactobacilli could lead to 
acceptability problems by regulatory agencies (Ribelles et al., 2012). Therefore, binding 
heterologous protein to peptidoglycan is more convenient to develop. 
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In this study, we constructed plasmids vector expressing EGFP and CWBD fusion 
proteins. The positive color response was found for LA4356, LG33323 and LS11741 cells, 
especially LA4356 and LG33323, which incubated with purified EGFP_SH3 fusion protein, 
whereas no color response was found for LA4356, LG33323 and LS11741 incubated with 
EGFP only. The results indicated that this predicted SH3 could be a candidate CWBD 
surface display system. The number of binding sites of CWBD could be quantified by 
measuring fluorescence on the cell wall, and then appropriate CWBD for specific LAB could 
be selected for different applications.   
4.5 Conclusion  
 In this study, predicted SH3 domain was successfully bound onto cell surface of 
LA4356, LG33323 and LS11741. It indicated SH3 domain may be a candidate for protein 
display. Moreover, we have problems to purified EGFP_lysM and EGFP_AcmA proteins. 
Protein expression or purification methods need to be modified in the future. Furthermore, 
target myelin epitopes of PLP, MOG and PLP/MOG will replace EGFP and bind to cell wall 
surface of lactobacilli. We were also attempting to bind SH3 or other two CWBD on the 
surface of other Gram-positive bacteria. This system would be attractive for the different 
purpose of delivery systems. 
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Table 4.1 Bacterial strains and plasmids 
Strains MJM# Plasmid Description of bacteria strain and plasmid Source 
E.coli Top10 MJM351 NA Cloning host Invitrogen 
 MJM355 pUC19 ApR, cloning vector Invitrogen 
 MJM334 pUC-PLP/MOG ApR, pUC19 backbone, PLP/MOG inserted This Study  
 MJM336 pUC-LysM 
ApR, pUC19 backbone, L.gasseri LysM 
inserted 
This Study  
 MJM337 pUC-SH3 
ApR, pUC19 backbone, Lysozyme SH3 
inserted 
This Study  
 MJM338 pUC-AcmA ApR, pUC19 backbone, AcmA CWBD inserted This Study  
 MJM353 pRSETB ApR, expression vector Invitrogen 
E. coli MC1061 MJM349 pEGFP-N1 KmR, encodes the GFPmut1 variant BD Biosciences 
E.coli BL21 
(DE3) plysS   
MJM326 NA Expression host Invitrogen 
 MJM339 pPLP/MOG-LysM 
ApR, CamR; pRSETB backbone, PLP/MOG and 
L.gasseri LysM inserted 
This Study  
 MJM340 pPLP/MOG-SH3 
ApR, CamR; pRSETB backbone, PLP/MOG and 
Lysozyme SH3 inserted 
This Study  
 MJM341 pPLP/MOG-AcmA 
ApR, CamR; pRSETB backbone, PLP/MOG and 
AcmA inserted 
This Study  
 MJM345 pEGFP-LysM 
ApR, CamR; pRSETB backbone, EGFP and 
L.gasseri LysM inserted 
This Study  
 MJM346 pEGFP-SH3 
ApR, CamR; pRSETB backbone, EGFP and 
Lysozyme SH3 inserted 
This Study  
 MJM347 pEGFP-AcmA 
ApR, CamR; pRSETB backbone, EGFP and 
AcmA CWBD inserted 
This Study  
 MJM362 Pegfp ApR, CamR; pRSETB backbone, EGFP inserted This Study 
ApR, Ampicillin resistant; CamR, Chloramphenicol resistant 
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Table 4.2 Primers used in this study 
  
Primers Sequence Restriction site1 
M13For-21 GTAAAACGACGGCCAGT 
 M13Rev-24  AACAGCTATGACCATG 
 LZ_EGFP_F CGCGGATCCGATGGTGAGCAAGGG BamHI 
LZ_EGFP R-XhoI  CCGCTCGAGCTTGTACAGCTCGT XhoI 
LZ_pRSETB_F TCGGGATCTGTACGACGATG 
 LZ_pRSETB_R CAGCTTCCTTTCGGGCTTTG 
 Restriction enzyme sites are underlined 
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Figure 4.1 Gene map of an expression vectors for cell wall binding domain and genes of 
PLP/MOG epitopes ligated into pRSETB. Derivative of pRSET-B, which contains T7 
promoter, ribosome-binding site, His tag, EGFP, cell wall binding domain.   
(A) 
              
 
 
          
Plasmid  Target protein Size of nucleotides Protein weight 
 
pEGFP-LysM 
 
EGFP_LysM 
 
916 bp 
 
33.9kDa 
 
pEGFP-SH3 
 
EGFP_SH3 
 
1468 bp 
 
53.9kDa 
 
pEGFP-AcmA 
 
EGFP_AcmA 
 
1360 bp 
 
49.0kDa 
 
        
      
(B)       
 
      
 
 
 
 
       
    
 
 
Plasmid  Target protein Size of nucleotides Protein weight 
 
pPLP/MOG-LysM 
 
PLP/MOG_LysM 
 
1156 bp 
 
43.0kDa 
 
pPLP/MOG-SH3 
 
PLP/MOG_SH3 
 
1707 bp 
 
63.0kDa 
 
pPLP/MOG-AcmA 
 
PLP/MOG_AcmA 
 
1599 bp  
 
58.1kDa 
T7 6XHis EGFP STOP CWBD 
T7 6XHis PLP/MOG STOP CWBD 
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Figure 4.2 SDS-PAGE of total, soluble and insoluble bacterial lysates from recombinant E. 
coli BL21 (DE3). It contains pEGFP, pEGFP_LysM, pEGFP_AcmA. T: total protein; S: soluble 
protein; I: insoluble protein. EGPF (27 kDa); EGFP_LysM (33.9 kDa); EGFP_SH3 (53.9 kDa); 
EGFP_AcmA (49.0 kDa).  
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Figure 4.3 Fluorescence micrographs of the binding of the fusion protein EGFP_SH3 and 
EGFP to LG33323, LA4356, LS11741.
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 SUMMARY AND FUTURE DIRECTION CHAPTER 5
Therapies of MS disease are still limited, and most of the current clinic treatments have 
side effects. Lactobacillus spp. as an oral delivery system is a promising method for oral 
tolerance induction for MS.  Lactobacillus spp. could be developed as a potential oral 
delivery vehicle because of their GRAS status. There are two strategies that have been 
discussed in this thesis. Recombinant lactobacilli could be used as a suitable candidate of 
heterologous epitopes. We described the construction of antigen-presenting plasmid, 
which either secreted myelin epitopes to the environment or anchored them to the exterior 
cell surface of recombinant Lactobacillus spp. However, there are many problems to make 
lactobacilli to express protein, such as cloning, construction, transformation and protein 
expression. An alternate strategy explored the non-covalent attachment of myelin protein 
to the cell wall of Lactobacillus spp. via cell wall binding domains. Through working with 
these domains, we found that L. gasseri ATCC 33323 Lysozyme M1 – bacterial SH3 domain 
can successfully bind to the exterior cell surface to L. acidophilus ATCC 4356, L. gasseri 
ATCC 33323, and L. salivarius ATCC 11741. Therefore, SH3 domain may be a good tool for 
oral administration by binding heterologous epitopes to lactobacilli. 
Through working with this project, we summarized several points for future study.  
First, the strong constitutive promoter could cause difficulties of cloning and protein 
expression in the first strategy (chapter 3). It may be better to switch pgm promoter to a 
lower expression level promoter. In the second strategy (chapter 4), the stability of fusion 
proteins on the cell surface to lactobacilli is very significant at different temperatures and 
pH. Lately, myelin epitopes need to replace GFP and be displayed on the cell surface of 
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lactobacilli. Moreover, the animal data is critical to assess its potential as a therapeutic for 
MS. Once the animal experiments are complete, we can reevaluate our approach. For 
example, we will know which lactobacilli strain provides the optimal results based on our 
application. Ultimately, the clinical trial of lactobacilli as oral delivery system is necessary 
to evaluate the usability for human.  
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APPENDIX A CHAPTER 3 PLASMID MAP 
(Sequence of the plasmids can be found in S:\Miller Lab\Luyu Zhang\Chapter 3\Final 
plasmid) 
 
 
 
  
pMJM-8
4582 bps
1000
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4000
IBtg
INco
IIBan
ICRIEco
ISac
XIBst
IAle
IBtg
IISac
INot
IAco
IEag
IXba
ISpe
HIBam
ISma
IXma
IPst
RIEco
RVEco
dIIIHin
ICla
IAcc
cIIHin
ISal
XIPsp
IXho
O109IEco
IApa
IIBan
OMIPsp
Em
RepA
cat'
ORF-2
'cat
Figure A.1 Map of pMJM-8. Multiple Cloning Site (MCS) showed by restriction enzymes 
sites. Em, Erythromycin. 
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pMJM-13 
5682 bps
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4000
5000
II 4097Sac
I 4454Xba
I 4739Spe
HI 5225Bam
Em
RepA
cat'
ORF-1
Figure A.2 Map of pMJM-13. pFlpA_A; Secreted and anchored C. jejuni FlpA DII. ORF-1 
represents C. jejuni FlpA DII and anchored genes. 
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pMJM-14 
5199 bps
1000
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5000
II 4097Sac
I 4454Xba
HI 4742Bam
Em
RepA
cat'
ORF-1
Figure A.3 Map of pMJM-14. pFlpA_S; Secreted and anchored C. jejuni FlpA DII. ORF-1 
represents C. jejuni FlpA DII and anchored genes. 
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PMJM19
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II 4097Sac
I 4454Xba
I 4985Spe
HI 5471Bam
Em
RepA
cat'
ORF-1
Figure A.4 Map of pMJM-19. pPLP_A; Secreted and anchored PLP epitopes. ORF-1 
represents PLP epitopes and anchored genes. 
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I 4454Xba
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cat'
ORF-1
Figure A.5 Map of pMJM-20. pMOG_A; Secreted and anchored MOG epitopes. ORF-1 
represents MOG epitopes and anchored genes. 
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II 4097Sac
I 4454Xba
I 5414Spe
HI 5900Bam
Em
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cat'
ORF-1
Figure A.6 Map of pMJM-21. pPLP/MOG_A; Secreted and anchored PLP/MOG epitopes. 
ORF-1 represents PLP/MOG epitopes and anchored genes. 
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cat'
ORF-1
Figure A.7 Map of pMJM-22. pPLP_S; Secreted PLP epitopes. ORF-1 represents PLP epitopes. 
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cat'
ORF-1
Figure A.8 Map of pMJM-23. pMOG_S; Secreted MOG epitopes. ORF-1 represents MOG 
epitopes. 
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cat'
ORF-1
Figure A.9 Map of pMJM-24. pPLP/MOG_S; Secreted PLP/MOG epitopes. ORF-1 represents 
PLP/MOG epitopes. 
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APPENDIX B CHAPTER 4 PLASMID MAP 
(Sequence of the plasmids can be found in S:\Miller Lab\Luyu Zhang\Chapter 4\Codon 
Optimized Genes\Ligation Products 5-21-2014) 
 
 
 
pMJM35
4556 bps
1000
2000
3000
4000
BamHI 192
XhoI 1155
HindIII 1902
ORF-1
Ampicil l in
Figure B.1 Map of pMJM-35. pPLP/MOG_SH3; Derivative of pRSET-B with PLP/MOG 
epitopes gene and Lysozyme domain SH3 from L. gasseri. ORF-1 represents insert. 
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Figure B.2 Map of pMJM-36. pPLP/MOG_AcmA; Derivative of pRSET-B with PLP/MOG 
epitopes gene and AcmA domain from L. lactis subsp. cremoris. ORF-1 represents insert. 
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2000
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XhoI 1155
HindIII 1794
ORF-1
Ampicil l in
92 
 
Figure B.3 Map of pMJM-37. pPLP/MOG_LysM; Derivative of pRSET-B with PLP/MOG 
epitopes gene and LysM, LysM domain from L. gasseri. ORF-1 represents insert. 
 
pMJM37
4005 bps
1000
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XhoI 1156
HindIII 1351
ORF-1
Ampicil l in
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Figure B.4 Map of pMJM-40. pEGFP_LysM; Derivative of pRSET-B with EGFP gene from 
pEGFP-N1 and LysM domain from L. gasseri.  ORF-1 represents EGFP gene. 
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ORF-1
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Figure B.5 Map of pMJM-41. pEGFP_SH3; Derivative of pRSET-B with EGFP gene from 
pEGFP-N1 and Lysozyme SH3 domain from L. gasseri. ORF-1 represents EGFP gene. 
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ORF-1
Ampicil l in
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Figure B.6 Map of pMJM-42. pEGFP_AcmA; Derivative of pRSET-B with EGFP gene from 
pEGFP-N1 and AcmA domain from L. lactis subsp. cremoris. ORF-1 represents EGFP gene. 
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Figure B.7 Map of pMJM-44. pEGFP; Derivative of pRSET-B with EGFP gene from pEGFP-
N1 ORF-1 represents EGFP gene. 
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